Identification Of Stimulant Misuse And Malingering Of Symptoms Of Attention Deficit Hyperactivity Disorder by Ramachandran, Sujith
University of Mississippi 
eGrove 
Electronic Theses and Dissertations Graduate School 
2017 
Identification Of Stimulant Misuse And Malingering Of Symptoms 
Of Attention Deficit Hyperactivity Disorder 
Sujith Ramachandran 
University of Mississippi 
Follow this and additional works at: https://egrove.olemiss.edu/etd 
 Part of the Public Health Commons 
Recommended Citation 
Ramachandran, Sujith, "Identification Of Stimulant Misuse And Malingering Of Symptoms Of Attention 
Deficit Hyperactivity Disorder" (2017). Electronic Theses and Dissertations. 741. 
https://egrove.olemiss.edu/etd/741 
This Dissertation is brought to you for free and open access by the Graduate School at eGrove. It has been 
accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of eGrove. For more 
information, please contact egrove@olemiss.edu. 
 
 
 
 
  
IDENTIFICATION OF STIMULANT MISUSE AND MALINGERING OF SYMPTOMS OF 
ATTENTION DEFICIT HYPERACTIVITY DISORDER 
 
 
A Dissertation  
presented in partial fulfillment of requirements  
for the degree of the Doctor of Philosophy  
in the Department of Pharmacy Administration 
The University of Mississippi 
 
 
 
 By 
Sujith Ramachandran 
May 2017 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © 2017 by Sujith Ramachandran 
All rights reserved
 
 
ii 
 
ABSTRACT 
 
 It was estimated in 2013 that 54.3 million individuals reported overall lifetime prevalence 
of prescription drug abuse, and 16.7 million individuals reported misusing or abusing 
prescription drugs in the past year. This study focuses on the abuse of psychostimulants, 
popularly used for treatment of Attention Deficit Hyperactivity Disorder (ADHD). It is estimated 
that 10 to 30% of college students might be abusing stimulants, mostly for academic purposes. 
The incidence of stimulant related ER visits has nearly doubled in the last decade. It is also 
estimated that 10 to 50% of ADHD evaluations in a University setting might be exaggerated or 
malingered. This study, in three parts, explored the feasibility of identification of prescription 
stimulant abuse using large databases, developed a subtle behavioral self-reported scale, the 
Subtle ADHD Malingering Screener (SAMS), for use in the primary care setting to identify 
malingering among individuals reporting symptoms of ADHD, and compared the sensitivity of 
the SAMS to other existing scales. The first paper identified two latent classes in the stimulant 
user population based on risk factors for abuse identified from literature. The second paper 
developed a 10-item 2-factor screener instrument, the SAMS, with satisfactory reliability and 
factorial validity. The third paper calculated a cut-off score for the SAMS, and estimated a 
sensitivity of 90.3% and a specificity of 80.1% toward malingering of ADHD symptoms. This 
dissertation pursued innovative methods to help in the early identification of prescription 
stimulant abusers and malingerers, in order to reduce overdiagnosis of ADHD, and abuse of 
prescription stimulants. 
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CHAPTER 1 
INTRODUCTION TO PRESCRIPTION STIMULANT ABUSE: A REVIEW OF 
PREVALENCE, SOCIETAL IMPACT, SOURCES, AND EFFECT OF ABUSE 
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INTRODUCTION 
Introduction to prescription drug abuse
The United States’ War on Drugs is an extensive legal, economic, and sociocultural effort 
to change the fact that a nation that comprises only 5% of the world’s population consumes over 
25% of its illicit drugs (Zedido & Wheeler, 2012). The war on the use of illicit drugs has been 
mostly inefficient and ineffective, and has overshadowed the problem of abuse of prescription 
drugs (Zedido & Wheeler, 2012). An initial spotlight on prescription drugs was brought by the 
White House Conference on Prescription Drug Abuse in 1980 that pointed out the high rates of 
illness and death associated with misuse and abuse of prescription drugs (Wilford et al., 1994). 
While some efforts were made to address this issue by the White House and the American 
Medical Association (AMA), the problem has only grown worse (Wilford et al., 1994). In 2011, 
the Office of National Drug Control Policy declared prescription drug abuse a public health crisis 
in the US (ONDCP, 2011).  
To facilitate a discussion of prevalence and to explore ways to mitigate this growing 
problem of Prescription Drug Abuse (PDA), a thorough understanding of the terms used to 
describe PDA is necessary. According to the Substance Abuse and Mental Health Services 
Administration (2007), nonmedical use of a psychotherapeutic drug is defined as “use of a 
prescription medication that was not prescribed for the user or taking a drug only for the 
experience or feeling it may cause.” Compton & Volkow (2006) defined prescription drug abuse 
as, “any intentional use of a medication with intoxicating properties outside of a physician’s 
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prescription for a bonafide medical condition, excluding accidental use.” By using the term 
“intoxicating properties” Compton & Volkow (2006) excluded classes of medications abused for 
reasons other than euphoria, such as prescription stimulants, which the Division of Population 
Surveys had included with its “experience or feeling” definition. These two definitions 
demonstrate the range of definitions for PDA in extant literature and the disagreements between 
them. Boyd & McCabe (2008) explain that defining abuse can be challenging because misuse of 
controlled prescription medications can happen by people who misuse someone else’s 
prescription and also by those who misuse their own prescriptions without a physician’s 
knowledge. Recognizing the problem of defining such  diverse behavior, Smith et al. (2013) 
conducted a systematic review of definitions of all forms of “misuse, abuse and related events” 
and proposed their own definitions for each type of activity. They clarify that a misuse event 
signifies any intentional therapeutic use of a drug product in an inappropriate way; and an abuse 
event signifies any intentional, non-therapeutic use of a drug product, even once, for the purpose 
of achieving a desirable psychological or physiological effect. This definition of misuse is broad, 
it allows researchers to capture various forms of misuse, based on the type of medication being 
misused, the motives and techniques for misuse, and the methods of acquiring the medication. 
According to Boyd & McCabe (2008), there are four types of PDA possible depending on 
whether the prescription belong to the abuser or someone else, and whether the motivation for 
use was for the purpose of self-treatment or euphoria.  
The focus of this study is on the abuse or misuse of psychostimulants commonly 
prescribed for diagnoses such as Attention Deficit Disorder (ADD) and Attention Deficit 
Hyperactivity Disorder (ADHD). Stimulant abuse can occur in multiple forms such as the abuse 
of Schedule II stimulants such as cocaine – which are mostly illegally manufactured, rather than 
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diverted from legal prescriptions – or the abuse of Schedule I stimulants such as ecstasy or 3, 4 – 
methylenedioxy – methamphetamine (MDMA) – which are not available legally. This study will 
focus on abuse of drugs which are available legally and are mostly acquired through prescription 
diversion.  Any further mention of prescription stimulants in this document will refer to the drugs 
used to treat ADHD, unless specifically mentioned. The specific goals of this dissertation will be 
to help develop strategies to prevent abuse of prescription psychostimulants by identifying 
individuals who attempt to acquire prescriptions for the purpose of misuse, abuse or drug 
diversion. Over the course of chapters 2 to 4, this dissertation will attempt to identify individuals 
misusing prescription stimulants using a latent class analysis of known risk factors from 
administrative claims data, and by developing a subtle scale that can be administered in the 
physician’s office during the diagnosis of ADHD or ADD. A combination of both of these 
techniques, refined by thorough careful study, will help curb misuse or abuse of prescription 
stimulants. The rest of this chapter will deal with the impact of prescription drug abuse (with a 
special focus on stimulant abuse), the prevalence of stimulant abuse, intentions of stimulant 
abuse, a review of their impact on academic performance, and commonly available sources of 
stimulants for abuse. 
   
Prevalence of PDA 
It was estimated in 2013 that 54.3 million individuals reported overall lifetime prevalence 
of PDA, and 16.7 million individuals reported misusing or abusing prescription drugs in the past 
year. Of the 16.7 million individuals misusing prescription drugs, over 12.5 million were using 
opioids, 6 million were using tranquilizers and 3.3 million were using stimulants. The number 
individuals misusing prescription drugs was greater than the number of illicit drug users 
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combined (such as heroin, cocaine, ecstasy, and hallucinogens), and is second only to the 
prevalence of marijuana use (SAMHSA, 2013a). PDA cost the system $181 billion in 2002 
(Manchikanti, 2006; ONDCP, 2004). The prevalence of PDA has increased by more than 250% 
in the last 2 decades. Between 1992 and 2003, there was an 94% increase in the number of adults 
abusing controlled substances (Bollinger et al., 2005). The impact of this increase can be seen in 
the change in frequency of hospitalizations and emergency room visits attributed to PDA. 
According to the Drug Abuse Warning Network (DAWN), between the years 2004 and 2008, 
medical emergencies due to PDA increased 81% and emergency room visits increased 97%. In 
2008 alone, 54% of all drug related ER visits were caused by PDA (SAMHSA, 2011).  
In recent years, a new group of individuals, i.e., young adults enrolled in colleges and 
schools, has emerged as a prominent abuse population. Between 1992 and 2003, there was a 
212% increase in the number of 12 to 17 years olds abusing controlled substances, whereas the 
prevalence among adults grew by only 85% (Bollinger et al., 2005). About 13% of 18 to 25 year 
olds engage in PDA, compared to 7% in the 12 to 17 year age group (NIDA, 2013). 
 
Prescription Stimulants 
 Stimulants are a class of psychoactive drugs that can improve cognition. They include 
illegal substances such as cocaine, and crystal meth; and legal prescription drugs such as 
Adderall (dextrompehtammine), Ritalin (methylphenidate), and Concerta (methyphenidate). 
They are commonly prescribed to treat symptoms of Attention Deficit Hyperactivity Disorder 
(ADHD). Stimulants are known to reduce hyperactivity, impulsivity, inattentiveness, socially 
aggressive behavior, and increase vigilance, reaction time, task persistence, productivity, 
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working memory, handwriting, fine motor speed, energy levels, alertness, self-esteem, 
coordination, elevated mood, reduced appetite, and extended wakefulness among those who truly 
have ADHD (Barkley et al., 2003; Zullig & Divin, 2012). After a thorough review of the effect 
of stimulants on various characteristics related to academic performance, Smith & Farah (2011) 
conclude that stimulants enhance declarative learning, working memory, cognitive control in 
some individuals and might possibly cause cognitive enhancement in some others, but these 
effects were too small to actually make a difference. However, most of these conclusions stem 
from studies involving students with ADHD, meaning these results cannot be extended to 
students without ADHD who might be misusing stimulants.  
While the positive effects of stimulants on academic performance, in individuals with or 
without ADHD, lacks substantial evidence, stimulants are known to cause side-effects. The 
commonly mentioned side-effects include insomnia, headaches, irritability, nervousness, tics, 
significant weight loss, anxiety, anorexia, gastrointestinal distress, hallucinations (in the form of 
amphetamine psychosis), talkativeness, agitation, anger, paranoia, delusions, personality 
changes, mood swings, cardiovascular complications, and hypertension (Barkley et al., 2003; 
Hamilton, 2009; White, Becker-Blease & Grace-Bishop, 2006). Charach, Ickowicz & Schachar 
(2006) conducted a 5-year cohort study and found that while stimulants can improve symptoms 
of ADHD for up to 5 years in children, adverse effects tend to persist over the longer term. The 
FDA has also issued a blackbox warning for cardiovascular complications for prescription 
stimulants. The use of stimulants, even if taken legitimately, can result in increased Emergency 
Room (ER) visits (Miller et al., 2004). The number of stimulant-related ER visits have actually 
more than doubled between 2005 and 2010, and are responsible for approximately 40,000 ER 
visits per year (SAMHSA, 2013b).  
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While long-term data on effects of stimulant use is scarce, two effects have been studied 
by many researchers. The first is the effect of stimulant use on future substance abuse. Some 
studies have shown that use of stimulants is correlated with future substance abuse (Barkley et al, 
2003). Other studies show that ADHD medication actually has a protective effect against future 
substance abuse (Biederman, 1999), while yet others have found no relationship between the two 
(Molina et al., 2013; Kaloyanides et al., 2007). The problem with most of these studies is that 
they cannot account for the bias of the abuse liability of the ADHD patient independent from the 
ADHD medication. In other words, they cannot assess how likely the subject would be to engage 
in substance abuse had he not received the ADHD prescription. Therefore, while available 
evidence raises some concerns about future effect of stimulant use, it is mostly inconclusive.  
The second long-term effect of stimulants concerning younger patients is that of effect on 
growth rates. Several researchers have found that long-term use of stimulants can cause stunted 
growth rates among children (Toomey et al., 2003; Swanson et al., 2006; Charach et al., 2006; 
Swanson et al., 2007). In addition to the negative effect on growth rates, it was also found that 
children taking stimulants do not show rebound growth after drug use is discontinued (Swanson 
et al., 2007). The only study that did not find a significant effect of stimulant use on long-term 
growth rates was limited by a small sample size (Zachor et al., 2006). Despite these side-effects, 
White, Becker-Blease & Grace-Bishop (2006) report that about 79% of those taking stimulants 
report that they have no concern about stimulant abuse. 
Abuse of stimulants can also cause depression (Teter et al., 2010) and addiction or drug 
dependence (White, Becker-Blease, & Grace-Bishop, 2006). Prescription stimulants used for 
treatment of ADHD are classified as a Schedule II controlled substance because they have a high 
abuse liability, and cause withdrawal effects such as depression, anxiety, and severe fatigue 
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(Cohen, 2013). Manchikanti (2006) summarizes that prescription stimulants like 
methylphenidate have a lot in common with cocaine. They both bind to the similar sites in the 
brain and cause an increase in dopamine levels which leads to euphoria. While oral doses of 
stimulants might not cause a rush of dopamine equivalent to that of cocaine, it is reported that 
high doses of stimulants, taken by oral or intranasal routes, can cause high risk of addiction. Co-
ingestion with other drugs can also increase abuse liability (White, Becker-Blease & Grace-
Bishop, 2006; Volkow & Swanson, 2003). Smith & Farah (2011) found that 1 in 20 users of 
stimulants actually meet the criteria for being drug dependent. Whiteside et al. (2015) found that 
21.8% of those taking stimulants had a strong desire to misuse on a weekly/daily basis and 8.6% 
had health, social, legal or financial problems which they would consider secondary to stimulant 
abuse. 
 
Epidemiology of stimulant abuse 
The National Institute on Drug Abuse identifies individuals between the ages of 18 and 
25 years as a high risk group for abuse of prescription drugs (NIDA, 2013). While opioids, 
marijuana and stimulants are all commonly abused in the college population, research suggests 
that stimulants are the most frequently abused drugs (Babcock & Bryne, 2000). McCabe et al. 
(2014) provide evidence that the problem of stimulant abuse is actually of greater concern in the 
young adult age group than other drugs. In the decade from 2003 to 2013, the use of opioids 
decreased among college-aged individuals and use of stimulants and frequency of use of 
stimulants increased in the same time period. They also found that high frequency use (3 or more 
occasions) was normative among stimulants whereas low frequency use (1 or 2 occasions) was 
normative among sedatives and opioids. 
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The true prevalence of prescription stimulant abuse in college and university settings is 
difficult to measure. A 2012 systematic review concluded that most studies found less than 5% 
stimulant abuse in the 12 to 17 year old age group (Young, Glover & Havens, 2012).  In the 18 
to 25 year old age group, many studies report a prevalence of 4 to 8% (Frankenberger, 1990; 
Zullig & Divin, 2012; Poulin, 2001; Teter et al., 2005; Johnston et al., 2014; Whiteside et al., 
2015; Novak et al., 2007); while others found a prevalence of 10% or higher in the same 
population (LeFever & Dawson, 1999; Rowland et al., 2002; Johnston et al., 2005; Marsh et al., 
2000; McCabe & West, 2013; White et al. 2006; Babcock & Bryne, 2000; Hall et al., 2005; 
Bavarian et al., 2013). Two longitudinal studies were conducted in this population and both 
reported higher rates than any of these other studies. Garnier-Dysktra et al. (2012) found that by 
the end of four years in college, 61.8% of students were offered stimulants and over 31% of them 
accepted. As part of a 10-year longitudinal study, Wilens et al. (2006) found that only 56% of 
students who were taking prescription stimulants actually had ADHD. 
Most of these estimates of prevalence of misuse or abuse of stimulants are obtained from 
direct online surveys where participants are asked to disclose any illicit use behavior. Because 
such use is considered unacceptable and, many times, these drugs are obtained illegally by 
prescription diversion, individuals may not be willing to disclose their behavior. Dietz et al. 
(2013) found that direct online surveys can only present an underestimate of true abuse 
prevalence. They administered a survey in Germany using an innovative technique that ensures 
respondent privacy, called Randomized Response Estimates, and found that the true prevalence 
of using stimulants and other cognitive-enhancing drugs is closer to 20%.  
The recent reports of increased levels of stimulant abuse are supported by the fact that the 
number of prescriptions being written for stimulants has also grown steadily (Fortuna et al., 
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2010; Paulozzi, Mack & Hockenberg, 2014). The prevalence of ADHD, usually estimated at 3 to 
7%, has also increased in the past few years (Visser et al., 2010). The CDC reports that 
legitimate use of stimulants for children under 18 has increased 5 times in the period from 1988-
1994 to 2007–2010 (National Center for Health Statistics, 2014). And while 75% to 97% of 
actual ADHD patients respond positively to stimulant treatment (Barkley et al., 2003), ADHD 
may also be over-diagnosed (Kube, 2002).  Angold et al. (2000) found that only 3.4% of their 
student sample actually had ADHD, but about 7.3% of them had prescriptions to treat ADHD. 
With a mean score of 3.54 on a scale of 1 to 5, a college student population surveyed by Hall et 
al. (2005) agrees that ADHD is over-diagnosed in the college population. Zgierska, Miller and 
Rabago (2012) explain that the rise in rate of prescriptions for stimulants might also be because 
patients are becoming more aware of stimulants and want to experiment with them, while 
physicians are under increased pressure to prescribe these medications to keep their patients 
satisfied. 
The most common reason for misuse of stimulants is to improve academic performance 
or concentration. Manchikanti (2006) reports that 43% of students use stimulants to help with 
their school work, 31% use them to deal with other problems, and 22% use them to get high. 
Hamilton (2009) reports that the most common motives were concentration and alertness. In a 
longitudinal study across four years of college, Garnier-Dysktra et al. (2012) found that curiosity 
was the primary motive in early years, but academic performance becomes the primary motive 
later in college. Teter et al. (2005) also found concentration to be the most common motive for 
stimulant misuse. Interestingly, they found that the respondents who had reported using 
stimulants “only to study” also reported use of alcohol and other drugs, used to get high, as often 
as those who used stimulants “to get high”, suggesting that very few individuals might actually 
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be using stimulants solely for the purpose of academic improvement. Other motives for abuse or 
misuse as reported by Teter et al. (2005), in their systematic review, include use as a study-aid 
for all-nighters, euphoria, recreational tool in combination with alcohol, and as a reinforcement 
tool. The academic motives also explain why young adults enrolled in colleges were more likely 
to abuse stimulants than those not enrolled in educational institutions (Teter et al., 2005). Only 
14% of stimulant abusers thought that stimulants lead to long-term academic achievements (Hall 
et al., 2005).  
Hall et al. (2005) found that 27% of students took stimulants during finals week, 15.5% 
took them before tests, and 12% took them when they “partied”. A 2010 National Survey of 
Counselling Centers found that 91% of college counselling directors believe that many students 
are facing severe psychological problems on campus. The prevalence of mental health illnesses 
on campus is rising and the odds of abusing stimulants among students who reported feelings of 
hopelessness, sadness, depression, and suicide attempts were 1.2 to 1.4 times that of students 
who did not report these incidents (Zullig & Divin, 2012). In fact, Arria & Dupont (2010) 
recommend that stimulant abuse can be used as a marker for academic difficulties and mental 
health problems. 
A study of the sources of drugs for abusers of stimulants found that 70% of abusers began 
use after starting college. Of the students abusing stimulants in college, 87.1% acquired drugs 
from friends who had prescriptions, 30.4% obtained them from acquaintances and 26.4% abused 
their own medications without the knowledge of their prescriber (Bavarian et al., 2013). Maxwell 
(2011) also found that obtaining drugs from a friend or relative was the most common way to 
acquire the drug (55%). They found that 18% of individuals abused their own prescription, 5% 
obtained drugs from a drug dealer or a stranger and 0.4% used the Internet to order their 
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medications. Other researchers have also found that obtaining drugs from a friend or a relative is 
by far the most common way for obtaining prescription drugs for the purpose of abuse 
(Lessenger & Feinberg, 2008; McCabe et al., 2014). More than half of college students thought it 
was easy or somewhat easy to acquire stimulants for illicit use and they obtained it at a cost of $1 
to $5 per pill (White, Becker-Blease and Grace-Bishop, 2006; Hall et al., 2005). Medication 
diversion, or the practice of using prescription medications for purposes other than their intended 
use, such as for selling or giving away, is incredibly common with stimulants. Anywhere from 
25% to 54% of individuals with abuse-liable prescriptions are approached for diversion of their 
medication (McHugh, Neilsen & Weiss, 2015; McCabe et al., 2014; McCabe et al., 2004, 2006; 
Poulin, 2001; Moline & Frankenberger, 2001). Wilens et al. (2006) found that 11% of 
individuals with legitimate ADHD prescriptions diverted their meds. Levine & Coupey (2009) 
found that 25% of students with a legitimate prescription gave away their medications.  
In a longitudinal study of stimulant misuse behaviors, Garnier-Dykstra et al. (2012) found 
that rates of misuse of one’s own prescription increased in later years in college. They suggest 
that this effect was possible because “upper classmen might seek out a diagnosis of ADHD as a 
means of ensuring a steady supply of prescription stimulants.” When Angold et al. (2000) found 
that more individuals had been prescribed stimulants than those who actually had ADHD, they 
explained that it was due to over-diagnosis, while it might very well also be explained by 
individuals who were faking ADHD for the sake of a prescription. White, Becker-Blease and 
Grace-Bishop (2006) explain that in order to curb stimulant abuse, attention should be paid to 
“whether students might fake ADHD or ADD symptoms to obtain stimulants for planned misuse 
or abuse or for resale.”  
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Feigning or malingering of ADHD 
Drug seeking behavior among stimulant abusers often manifests itself as students 
attempting to malinger attention deficit disorders in order to obtain legal prescriptions for 
stimulants. Hence, the ability of health practitioner to identify drug seeking behavior is crucial to 
decreasing drug abuse. However, in a study of opioid abuse, Weiner et al. (2013) found that 
physicians in the emergency room had a sensitivity of 63.2%, specificity of 72.7%, and positive 
predictive value of 41.2% for identifying drug seeking behavior. It is reported that only 19% of 
physicians were trained in school to identify drug diversion and only 40% of them were trained 
to identify PDA and addiction. In contrast, about 50% of pharmacists are trained to identify drug 
diversion or PDA and addiction. In addition, 43% of physicians do not ask about drug abuse 
when taking a patient’s history (Bollinger et al., 2005).  
Several studies show that 10% to 50% of students evaluated for ADHD in a University 
setting might be exaggerating or feigning their symptoms (Suhr et al., 2008; Sullivan, May & 
Galbally, 2007; Jasinksi & Ranseen, 2011; Harrison & Edwards, 2010; Pella et al., 2011). The 
promise of incentives such as access to stimulants, which can be misused or sold, and academic 
accommodations, provided to students diagnosed with learning disorder, and the decreasing 
stigma associated with rising awareness of the condition, has caused increasingly more students 
to feign or exaggerate their symptoms in order to be diagnosed with ADHD (Slick, Sherman & 
Iverson, 1999). There exists no standardized, statistically valid method for detection of 
malingering of ADHD (Harrison, Edwards & Parker, 2007), making it very easy to fake 
responses to appear ADHD-like on most ADHD diagnostic scales (Booksh et al., 2010; Harrison, 
& Edwards, 2010; Quinn, 2003). Jasinksi & Ranseen (2011) compiled evidence to show that 
ADHD can be faked very easily during physician interviews, on self-report inventories, observer 
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symptom ratings, cognitive measures and even tests of memory, executive function and 
attention. Symptom Validity Tests (SVT) provide the best opportunity at identifying malingerers 
among existing methods. However, even they suffer from poor sensitivity (35% to 63%, 
depending on the test) and are time intensive, and expensive (Jasinksi et al., 2011; Marshall et 
al., 2010; Jasinksi & Ranseen, 2011).  
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RESEARCH OBJECTIVES 
In order to better control the abuse of prescription stimulants among young adults 
enrolled in colleges, there exists a need to understand the stimulant use behavior, and to identify 
the individuals who attempt to feign symptoms of ADHD in order to gain access to the 
medication. The goal of this diisertation is to attempt to identify individuals misusing stimulants 
and prevent stimulant abuse by developing an innovative methodology to identify early abusers. 
The specific aims of this dissertation are 
1. To explore the feasibility of identification of prescription stimulant abuse using large 
databases (Paper 1). 
2. To develop a subtle behavioral self-reported scale, the Subtle ADHD Malingering Screener 
(SAMS), for use in the primary care setting to identify malingering among individuals 
diagnosed with ADHD (Paper 2). 
3. To test the ability of the newly developed scale, SAMS, to detect faking among adults 
diagnosed with ADHD and compare it to other existing scales (Paper 3). 
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ABSTRACT 
Background
An increase in prevalence of prescription stimulant abuse has led to concerns about stimulant-
related addiction, emergency room visits, and other adverse effects. The aim of this study is to 
explore the feasibility of the identification of prescription stimulant abuse by categorizing 
stimulant users using Mississippi Medicaid administrative claims data and Mississippi 
Prescription Monitoring Program data. 
Methods 
This study employed a retrospective design to follow a cohort of prescription stimulant users 
using data from Mississippi Medicaid administrative claims and the Mississippi Prescription 
Monitoring Program, for the years 2014 and 2015. Risk factors for stimulant abuse were used to 
characterize latent classes among prescription stimulant users. Predicted latent class membership 
was used to predict chances of being diagnosed with dependent or nondependent stimulant 
abuse. 
Results 
A latent class model with 2 classes was selected as the best fit for this sample. The first latent 
class, comprising 4.1% of the sample, was characterized by a significantly higher proportion of 
cash prescriptions, new starts, and significantly lower prevalence of ADHD, and fewer unique 
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pharmacies visited. However, latent class membership was not significantly predictive of 
diagnosis of stimulant abuse (p = 0.802).  
Conclusions 
This study shows the value of commonly used risk factors in identification of prescription 
stimulant abuse. It also categorizes the various patterns of use of prescription stimulants and tests 
its ability to predict stimulant abuse diagnoses. Further research is needed to test the validity of 
these latent classes in the prediction of stimulant abuse.  
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INTRODUCTION 
1.0 Introduction
Prescription stimulants such as amphetamine and methylphenidate are commonly prescribed 
to treat symptoms of Attention Deficit Hyperactivity Disorder (ADHD). These drugs are 
classified as schedule II controlled substances because they have a high abuse liability (Cohen, 
2013). It is estimated that over 3.3 million individuals misused stimulants in 2013 alone 
(SAMHSA, 2013). Between 2006 and 2011, the nonmedical use of prescription stimulants 
among adults increased by 67%, and stimulant-related emergency room visits have more than 
doubled (Chen et al., 2016). Repeated use of prescription stimulants can also lead to drug 
dependence or addiction among individuals with and without ADHD (Bollinger et al., 2005; 
National Center for Health Statistics, 2014). The prevalence of drug dependence is estimated to 
be 1 in every 20 stimulant users, and is steadily increasing (Bollinger et al., 2005; National 
Center for Health Statistics, 2014; Smith & Farah, 2011). Abuse of stimulants can lead to a 
variety of side-effects such as insomnia, headaches, significant weight loss, anxiety, delusions, 
mood swings, cardiovascular complications, and hypertension (Barkley et al., 2003; Charach et 
al., 2006; Hamilton, 2009; Smith & Farah, 2011; White, Becker-Blease & Grace-Bishop, 2009).  
An understanding of the patterns of use is essential to identification, treatment, and even 
prevention of stimulant misuse. Research about characteristics and patterns of drug use have 
been conducted in the area of alcohol abuse (Agrawal et al., 2006; Chiauzzi, DasMahapatra, & 
Black, 2013), and substance abuse (Carlson et al., 2005; Falck et al., 2005; Kelly et al., 2015; 
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Morasco & Dobscha, 2008; Patra et al., 2009; Sherman et al., 2009). For example, Sullivan et al. 
(2010) used data from Arkansas Medicaid and a commercial insurance plan to develop an opioid 
misuse score that correlates to possible indicators of misuse. Chiauzzi et al. (2013) classified 
college students into four different classes based on a combination of their alcohol and drug use 
frequencies. However, such research is lacking in the area of prescription stimulant abuse.  
1.1 Characteristics of stimulant misuse 
Stimulant use patterns can be challenging to characterize because of the varying frequencies 
of use among both legal and illegal users of stimulants. For example, individuals with legal 
stimulant prescriptions might take their medication every day or choose to use it infrequently, 
depending on their needs, and the severity of their symptoms (Caisley & Muller, 2012). 
Individuals misusing stimulants might also have varying patterns of use, depending on whether 
they are drug dependent, or if their motivation for misuse is for academic performance-related 
reasons (Garnier-Dysktra, et al., 2012; Moore et al., 2014). This varying frequency of use is also 
commonly seen among opioids; hence, several of the characteristics applicable to identification 
of opioid misuse can be used to help drive research in the identification of prescription stimulant 
misuse.  
Risk factors commonly used to identify misuse of opioids include doctor shopping, high 
frequency of prescriptions, familial availability of prescriptions, and early refills (Katz et al., 
2010; Morasco & Dobscha, 2008; Sansone & Sansone, 2012; Van den Bree et al., 1998). Several 
of these risk factors have been shown to be relevant in misuse of prescription stimulants. For 
example, Van den Bree et al. (1998) demonstrated the importance of familial substance abuse in 
identifying stimulant misuse. High doses of oral stimulants taken non-medically are known to 
cause drug dependence (NIDA, 2014). Doctor shopping has been demonstrated to be a 
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successful technique for acquiring prescription drugs for misuse or diversion, in cases of both 
opioids and stimulants (Sansone & Sansone, 2012; Worley, 2012).  
1.2 Objectives 
The objective of the current study is to explore the feasibility of identification of prescription 
stimulant misuse using, administrative claims data to identify and characterize latent classes of 
prescription stimulant users, and study the relationship between the membership in each latent 
class and the diagnosis of stimulant abuse.
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METHODS 
2.0 Materials & Methods 
2.1 Study design
This study employed a retrospective data analysis to follow a cohort of prescription 
stimulant users using data from the Mississippi Medicaid administrative claims and the 
Mississippi Prescription Monitoring Program, for the years 2014 and 2015. Risk factors for 
stimulant misuse were identified from the data and used to characterize latent classes of 
prescription stimulant users. Predicted latent class membership was then used to predict a distal 
outcome, i.e, the likelihood of being diagnosed with dependent or nondependent stimulant abuse. 
Approval was obtained from the University of Mississippi’s Institutional Review Board before 
researchers had access to the data. 
2.2 Data source 
The Mississippi Medicaid administrative claims data contains all claims paid for by 
Mississippi Division of Medicaid for beneficiaries enrolled in its fee-for-service or managed care 
plans. It contains separate datasets for pharmacy claims, inpatient claims, outpatient claims, and 
a beneficiary master file – that contains demographic and eligibility information of enrollees. 
Claims for Medicaid beneficiaries paid for with cash are not captured in this dataset. The 
Mississippi Prescription Monitoring Program (PMP) data were used in this study to capture the 
cash prescriptions of Medicaid beneficiaries. The patient ID in the PMP data was linked to the 
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beneficiary ID in the Medicaid data, offering the researchers comprehensive prescription 
information, hospital or outpatient use data, and diagnosis information.  
2.3 Timeline 
 The study used data from July 1st 2014 to June 30th 2015 to identify Mississippi Medicaid 
beneficiaries who were filling prescriptions for stimulants within the state of Mississippi. The 
first dispensing event for prescription stimulants during this period was labelled as the index 
prescription. The period ranging from January 1st 2014 to June 30th 2014 was used as a washout 
period to check for medication and diagnostic history. Individuals identified during the study 
period were followed up to December 31st 2015 in order to ensure that every participant included 
in the study had at least 6 months of follow up from their index date. 
2.4 Inclusion/exclusion 
All Medicaid beneficiaries needed to be continuously enrolled during the study period 
(January 2014 to December 2015). Participants were eligible if they were over 18 years of age at 
the beginning of the study period, could not have dual eligibility in Medicare, and could not be 
enrolled in long term care. Participants were also required to have at least 3 refills for stimulants 
during the study period (July 1st 2014 to December 31st 2015). 
2.5 Latent Class Indicators & Their Operationalization 
 Risk factors for drug misuse identified from literature were used as indicators for the 
latent class analysis. The risk factors included in this study were the number of refills for 
prescription stimulants during the study period, percentage of early refills, percentage of refills 
paid for with cash (i.e., not paid for by Medicaid), excess distance travelled to obtain stimulants, 
average number of stimulants per enrollee in a given zipcode, and the number of unique doctors 
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and pharmacies who have prescribed and dispensed stimulants, respectively. In addition to these 
variables, two categorical variables: whether or not the patient had a new start on stimulant 
therapy, and the presence of an ADHD diagnosis in the data were also included.  
 Total number of refills, number of early refills, and percentage of prescriptions paid for in 
cash indicate intentions of misuse or abuse. Early refills were operationalized as obtaining a refill 
2 or more days before the end of the supply from the previous prescription. Prescriptions paid for 
with cash were identified using the payment type variable found in the PMP database. Excess 
distance travelled to obtain stimulants indicates the number of times the patient travelled further 
than necessary to a doctor appointment for his/her stimulant prescriptions. It was operationalized 
as the number of times the participant has travelled more than the average distance travelled by 
all the Medicaid enrollees in his/her zipcode to obtain a stimulant prescription. Geographic 
variations were accounted for using the average number of stimulant prescriptions per eligible 
Medicaid enrollee in the zipcode in which the participant resides. Zipcode information for each 
beneficiary was obtained from the beneficiary master file. The number of unique pharmacies and 
doctors visited by each patient is used as a measure of doctor shopping, and was calculated using 
each of the patient’s visits during the follow up period. New therapy on prescription stimulants 
were defined as those patients who have no fills for stimulants during the 6 month washout 
period before their index prescription. Diagnosis for ADHD was identified using ICD9 and 
ICD10 codes present in the outpatient and inpatient Medicaid claims records of participating 
beneficiaries.  
2.6 Outcome Variables 
Medicaid beneficiaries who were found to be receiving treatment for dependent or 
nondependent stimulant abuse were used as the group of interest in this study. These patients 
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were identified from the ICD9 and ICD10 diagnosis codes found in the inpatient and outpatient 
claims records. These diagnosis codes are the closest approximation to a gold standard for 
identification of prescription stimulant abuse available in administrative claims data. Other 
demographic variables such as age, race, and gender were used as control variables in the 
analysis.  
2.7 Analysis  
Data management and analysis were conducted using MPlus (Muthen & Muthen, 1998) 
and IBM SPSS (Chicago, IL). Latent Class Analysis (LCA), using MPlus, was used to identify 
subgroups of individuals that were similar to each other based on chosen indicator variables, i.e., 
the risk factors for misuse (Lazarsfeld & Henry, 1968).  LCA was chosen because it uses model-
based posterior probabilities to obtain subgroups, instead of a measure of distance in multi-
dimensional space, such as that used in cluster analysis. It allows for latent classes with unequal 
variances and provides more interpretable results, while also being as reliable at prediction as 
discriminant analysis when using both categorical and continuous indicators (Carlson et al., 
2005; Magidson & Vermunt, 2002). Similar approaches of identifying latent classes among drug 
abusers have been applied in the past to better understand patterns and behaviors of individuals 
dependent on other drugs (Agrawal et al., 2006; Carlson et al., 2005; Chiauzzi et al., 2013; Falck 
et al., 2005; Kelly et al., 2015; Morasco & Dobscha, 2008; Patra et al., 2009; Sherman et al., 
2009). 
Decisions about model fit were based on fit statistics such as the Bayesian Information 
Criterion (BIC), the Akaike Information Criterion (AIC), the Adjusted BIC (aBIC), and the 
entropy statistic. In general, lower values of AIC, BIC or ABIC and higher values of entropy 
indicate greater class separation and higher precision in class assignments. The Lo-Mendel-
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Rubin Likelihood Ratio (LMR LR test) was used to choose the model with the appropriate 
number of latent classes (Carlson et al., 2005; Kelly et al., 2015). Most likely class membership 
for each observation was saved, and a logistic regression was performed, using SPSS, to identify 
the relationship between class membership (treated as an observed variable) and a combined 
endpoint of a diagnosis of diagnosis of dependent or nondependent stimulant abuse. Available 
demographic variables were used as covariates in the logistic regression. This regression was 
conducted in SPSS, instead of using the distal outcome option (DCATEGORICAL) in MPlus, 
because despite using true probabilities of class membership, the DCATEGORICAL feature 
does not provide an option to control for covariates (Asparouvhov & Muthen, 2014). The use of 
most likely class membership as an observed variable is considered an acceptable approach when 
covariates are present in the analysis (Clark & Muthen, 2009). However, the DCATEGORICAL 
option in MPlus was also performed as a sensitivity analysis.
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RESULTS 
3.0 Results 
3.1 Demographics
A total of 1022 Medicaid beneficiaries were eligible for the study. They were mostly 
female (70%), Caucasian (75%), and 31.7 years (SD: 10.99) old, on average. Most of the sample 
had a diagnosis of ADHD (83.6%), and 27.3% were identified as new starts on stimulant 
therapy. On average, 4% of the prescriptions were paid for in cash, and nearly 37% of refills 
were filled early. The average Medicaid beneficiary visited 2 unique pharmacies and 1.7 unique 
physicians for stimulant during the study period. Demographics of the study sample are provided 
in Table A1. 
3.2 Latent classes 
 A latent class model with the 2 classes was chosen as the final solution in this study. The 
3-class model had a significant LMR LR test, and lower values of AIC, and BIC, indicating 
satisfactory fit. However, the 3-class model provided a highly skewed class distribution with 
95.2% in Class 1, 4.1% in Class 2, and 0.5% in Class 3. The 3-class model also suffered from a 
non-positive definite first-order derivative product matrix due to model nonidentification, 
resulting in a lack of replicability in the best loglikelihood value, despite increasing the number 
of random starts. In contrast, the 2-class solution, despite having slightly higher values of AIC 
(41970.03 vs 40226.28), and BIC (42098.19 vs 40403.74), showed a significant LMR LR test,  
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Table A1: Demographics of the sample, and distribution across latent classes 
Characteristic 
n (%)/Mean[SD] 
Overall 
 (N = 1022) 
Class 1 
(N = 42) 
Class 2 
(N = 980) 
ADHD* 854 (83.6) 28 (66.7) 826 (84.3) 
New prescriptions* 279 (27.3) 19 (45.2) 260 (26.5) 
Race    
            Caucasian 768 (75.1) 33 (78.6) 735 (75.0) 
            African American 139 (13.6) 8 (19.0) 131 (13.4) 
            Other 114 (11.2) 1 (2.4) 113 (11.5) 
Female** 723 (70.7) 40 (95.2) 683 (69.7) 
Dependent abuse of stimulants 28 (2.7) 0 (0) 28 (2.9) 
Nondependent abuse of stimulants 32 (3.1) 3 (7.1) 29 (3.0) 
Composite endpoint 54 (5.3) 3 (7.1) 51 (5.2) 
Total number of prescriptions 11.8 [6.3] 11.1 [7.1] 11.8 [6.3] 
Number of pharmacies** 2.0 [1.4] 0.7 [1.0] 2.03 [1.4] 
Number of physicians 1.71 [1.0] 1.6 [1.1] 1.7 [1.0] 
Percent of cash prescriptions** 4.4 [17.7] 84.6 [19.6] 0.9 [4.7] 
Percent of early refills 36.9 [23.6] 41.4 [18.2] 36.7 [23.8] 
Average stimulants per beneficiary in a 
zipcode 
0.55 [1.4] 0.4 [0.3] 0.6 [1.4] 
Age* 31.7 [11.0] 35.9 [10.5] 31.6 [11.0] 
Note: * – p < 0.05; ** – p < 0.0001 
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and demonstrated satisfactory replicability in the best loglikelihood value. The 2-class model 
also had a high entropy value of 0.999. As stated by Carlson et al., (2005) “LCA classification 
should be driven by both statistics, and theory”, and classes must be “interpretable, and have a 
meaningful number of observations.” Therefore, for reasons of interpretability, model 
identification, and theoretical considerations, the 2-class model was chosen as the final solution 
(Geiser, 2013). 
Of the 1022 subjects included in the latent class analysis, 4.1% (42) were included in the 
Class 1, and 95.9% (980) were included in Class 2. The distribution of each of the latent class 
indicators and the demographic variables across the two classes is provided in Table 1. Class 1, 
which includes only 42 individuals, was significantly older, with more females, less prevalence 
of ADHD, higher prevalence of cash prescriptions, and a fewer number of pharmacies visited. 
The prevalence of cash prescriptions in Class 1 was significantly higher than that in Class 2 
(84.6% versus 0.9%). The percentage of early refills, though not statistically significantly, was 
also found to be higher in Class 1 than Class 2 (41.4% versus 36.7%). The smaller size of Class 
1, along with the distribution of risk factors, suggest that Class 1 might be representative of 
stimulant misuse population. Individuals classified into Class 2 might be representative of 
regular/legal stimulant use behavior.  
3.3 Prediction of stimulant abuse 
 The results of the 2-class solution indicate that Class 1 might be comprised of individuals 
likely to be misusing prescription stimulants. A logistic regression examining the effect of most 
likely class membership on dependent/nondependent prescription stimulant abuse, after 
controlling for demographic variables was not found to be significant (p = 0.802). The 
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demographic variable, race was dropped from the model because the distribution of race across 
the levels of the outcome variable were highly skewed leading to large standard errors.  
 Individuals in Class 1 had 1.17 times the odds of being diagnosed with prescription 
stimulant abuse, when compared with those in Class 2; however this increase in odds was not 
found to be significant (95% CI = 0.63 – 2.17; p = 0.802). When compared to males, females had 
1.55 times the odds of being diagnosed with prescription stimulant abuse, but this difference was 
not statistically significant (95% CI = 0.07 – 2.24; p = 0.239). Subject age was found to be 
significantly related to the outcome with an odds ratio of 1.03 (95% CI = 1.01 – 1.04; p = 0.047; 
Table A2).  
Table A2: Prediction of dependent/nondependent prescription stimulant abuse 
Variable Odds ratio 95% CI 
Class 1 1.2 0.63 – 2.17 
Female 1.6 0.07 – 2.24 
Age* 1.0 1.01 – 1.04 
Note: Reference categories: Class 1 – Class 2; Female – Male.  
Note: * – p < 0.05 
 
In addition to the logistic regression conducted using SPSS and most likely class 
membership as the focal independent variable, the distal outcome analysis was also conducted 
using the DCATEGORICAL option in MPlus without any covariates (Asparouhov & Muthen, 
2014). This approach takes into account measurement error and uncertainty of classification; the 
use of most likely class membership does not do so, which is an inherent limitation (Clark & 
Muthen, 2009). The DCATEGORICAL option has been suggested as the preferred method for 
analyzing categorical distal outcomes (Asparouhouv & Muthen, 2014). This analysis revealed no 
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significant relationship between class membership and the combined endpoint (chi square = 
0.226; p = 0.634), a finding consistent with the previous analysis.
 
  
 
 
47 
 
DISCUSSION 
4.0 Discussion
 This study attempts to develop a deeper understanding of the differences in stimulant use 
behaviors between abusers and non-abusers, using a latent class analysis to first classify 
individuals according to their behaviors. It is one of the first studies to attempt to exclusively 
characterize stimulant use behaviors, and validate the developed latent classes using stimulant 
abuse diagnoses identified from administrative claims data. The use of administrative claims data 
to identify misusers of prescription stimulants revealed critical insights that can help future 
research in this area. This study was also the first to use a combination of Medicaid 
administrative claims data and PMP data to comprehensively capture all use of stimulants while 
estimating the risk behaviors. 
 A latent class model with 2 classes was selected as the best fit in this study. Over 95.9% 
of the sample was classified in Class 2, with only 4.1% classified into Class 1. This distribution, 
while skewed, was in line with the expectation of identifying a small proportion of misusers 
present in the population. Class 1 (N = 42) was expected to be related to abuse behavior because 
individuals classified in this class also had a lower proportion of ADHD diagnoses, and a 
significantly higher proportion of cash refills, an indicator expected to be correlated with abuse 
(Inciardi et al., 2009). In contrast, other indicators expected to be positively correlated with 
abuse, such as the number of unique pharmacies visited was significantly lower in this class 
(Sansone & Sansone, 2012; Worley, 2012). The other doctor shopping indicator variable, 
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number of unique physicians visited, was not significantly different between the two classes. 
Perhaps this difference in the distribution of risk factors contributed to the non-significant 
prediction of stimulant misuse. 
The odds ratio from the validation procedures corresponding to latent class membership 
was not found to be statistically significant, indicating that behavioral risk factors of misuse were 
not predictive of stimulant misuse in administrative claims data. The practical significance of the 
latent classes needs to be judged within the context of the data used in this study. The diagnosis 
of dependent or nondependent stimulant abuse obtained from the medical records was the best 
available indicator for stimulant misuse. However, these diagnostic codes are used to identify 
abuse of both prescription stimulants and non-prescription illegal stimulants such as cocaine and 
heroin, leading to inaccurate capture of the outcome variable. There is also a possibility that 
stimulant abuse was underdiagnosed in the Medicaid population. Furthermore, individuals 
associated with risk behaviors such as cash refills, early refills, or doctor shopping might be 
diverting their prescriptions, and not misusing the medications themselves, and therefore will 
never be diagnosed with stimulant abuse. Finally, while the direction of relationship between 
stimulant abuse and latent class membership was in the right direction, perhaps the sample size 
of abusers was too small for a significant finding. It is possible that any combination of these 
reasons was responsible for the non-significant finding obtained in this study. The latent classes 
obtained in this study might still be indicative of stimulant misuse, but further research into the 
stimulant use behavior, perhaps using alternative validation techniques, is needed.  
4.1 Limitations & Conclusions 
 While this study was one of the first to characterize latent classes of stimulant users, it 
carries limitations derived from the datasets used. Administrative claims data, even combined 
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with PMP data often do not provide a complete picture of the patient’s healthcare use. It is 
possible that stimulant abusers filled prescriptions outside of state limits or obtained the 
medications illegally, both of which are not captured by available data. Other latent class 
indicators, such as presence of an ADHD diagnosis, prescription history for identification of new 
prescriptions were limited by the fact that only 6 months of historical data were available. The 
datasets used in this study were merged based on an encrypted beneficiary identification number, 
and it is possible that some claims were wrongly attributed to other patients. Thorough quality 
checks were conducted on the PMP data prior to this study to ensure they were linked to the 
correct beneficiary identification number, and this error, if existing, is expected to be minimal. 
The limitations of the outcome variable could have influenced the validation of the latent 
classes, and the prediction of stimulant abuse status. It is possible that many individuals 
classified in Class 1 were in fact abusing prescription stimulants, but had not been diagnosed; but 
there was no way to know their true misuse status from the data. Hence the findings of the 
prediction of stimulant misuse using latent classes need to be treated with caution and probably 
represent an underestimation. It is possible that alternative validation mechanisms with more 
reliable identification of misusers might have discovered a correlation with the latent classes 
obtained in this study. 
 This study demonstrates the value of latent class techniques to help identify variations in 
patterns of stimulant use, while also displaying the limitations of administrative claims databases 
in capturing true misuse status. Prescription stimulant misuse has increased in recent years (Chen 
et al., 2016), and techniques to identify this misuse need to be further researched to help address 
this problem.
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ABSTRACT 
Objective Development of a behavioral, self-reported, subtle scale, called the Subtle ADHD 
Malingering Screener (SAMS), for use in the primary care setting to identify malingering among 
individuals reporting symptoms of ADHD. 
Method This study employs a cross-sectional experimental design using a self-administered 
computer-based survey distributed to conveniently sampled groups of college students with and 
without ADHD. Respondents were classified into three groups: the ADHD group, comprised of 
individuals with ADHD; the Control group, comprised of individuals without ADHD, and the 
Malingerer group, comprised of individuals without ADHD who were instructed to feign ADHD. 
Factor analysis and psychometric testing were conducted to develop a final scale that can 
distinguish the Malingerer group from the other groups. 
Results A ten-item, two-factor solution was obtained with satisfactory model fit, reliability, and 
construct validity. The psychological factor contained six items, and the academic factor 
contained four items. Means for individual items and the sum subscale scores were all 
significantly different among the three study groups. 
Conclusion The SAMS presents an innovative approach to identify malingering of ADHD 
symptoms, reduce overdiagnosis of ADHD, and address abuse of prescription stimulants. It is 
short, easy to administer, and presents significant potential for direct use in the clinical setting. 
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INTRODUCTION 
1. Introduction
The abuse of prescription stimulants, typically prescribed for ADHD, on college 
campuses has been increasing in the past few years (Bollinger et al., 2005; Chen et al., 2016). 
The Substance Abuse and Mental Health Services Administration identifies individuals between 
the ages of 18 and 25 years as a high risk group for abuse of prescription drugs (SAMHSA, 
2010). College-aged students use more stimulants than their counterparts not enrolled in college 
(Johnston et al., 2011; Johnston et al., 2016). Garnier-Dysktra et al. (2012) estimate that the 
prevalence of prescription stimulant abuse in college populations can range up to 31%. Between 
2006 and 2011, the nonmedical use of prescription stimulants among adults increased by 67%, 
and stimulant-related emergency room visits have more than doubled (Chen et al., 2016).  
1.1 Malingering of Attention Deficit Hyperactivity Disorder (ADHD) 
Most adults misusing prescription stimulants obtain the drugs from friends/family 
(Bavarian et al., 2013; Maxwell, 2011; Lessenger & Feinberg, 2008; McCabe et al., 2014). 
Students who misuse stimulants might also be interested in seeking out a diagnosis of ADHD 
(Zgierska, Miller and Ribago, 2012; Garnier Dysktra et al., 2012). Obtaining an ADHD 
diagnosis offers students means to acquire prescription stimulants legally and additional 
privileges such as extra time on tests, and isolated test environments, that most colleges and 
universities offer to accommodate students with learning diabilities (Young & Gross, 2011; 
Jasinksi & Ranseen, 2011). These benefits create external incentives that encourage malingering 
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behavior (Slick, Sherman & Iverson, 1999; Binder, 1992). Researchers estimate that 20% to 50% 
of college students might be exaggerating or malingering about their ADHD symptoms during an 
evaluation (Suhr et al., 2008; Sullivan, May & Galbally, 2007; Harrison, 2006). 
1.2 Detection of Malingering 
Malingering of ADHD symptoms in the physician’s office can be fairly easy (Quinn, 
2003; Fisher & Watkins, 2008; Harp et al., 2011; Jachimowicz & Geiselman, 2004). This is 
because it is difficult to accurately diagnose ADHD, and because physicians are often not 
adequately equipped to identify cases of malingering (Harrison, 2006; Bollinger et al., 2005). 
Tools commonly used for diagnosing ADHD, such as self-report inventories, observer symptom 
ratings, cognitive measures and test of executive functions, can all be faked easily (Quinn, 2003; 
Fisher & Watkins, 2008; Harp et al., 2011; Jachimowicz & Geiselman, 2004). Symptom validity 
tests often perform better at detection of malingering, but they are usually very expensive, time 
consuming, and require an expert for administration and interpretation (Jasinksi & Ranseen, 
2011).  
In order to detect malingering of ADHD, there is a need for tools that are short, 
economical, sensitive, and easy to administer, score, and evaluate. Subtle scales can offer all of 
these features, but they have not received much attention in the context of ADHD (Burkhart, 
Gynther & Christian, 1978). Popular examples of subtle scales include the Minnesota 
Multiphasic Personality Inventory (MMPI; Hathaway & McKinley, 1940) and the Substance 
Abuse Subtle Screening Inventory (SASSI; Miller, 1985), which are used to detect malingering 
of any mental illness, and for alcohol and substance abuse, respectively. Subtle subscales present 
in the MMPI and the Personality Assessment Inventory (PAI) have been used to identify 
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malingering of ADHD, but these scales were not designed specifically for ADHD, and hence 
they show poor sensitivity (Harp et al., 2011; Young & Gross, 2011; Rios & Morley, 2013). 
There is a need to develop subtle scales, grounded in theory, and tailored to identify malingering, 
especially in the context of ADHD (Musso & Gouvier, 2012). 
1.3 Objective 
This study aims to develop a behavioral self-reported Subtle ADHD Malingering 
Screener (SAMS), for use in the primary care setting to identify malingering among individuals 
reporting symptoms of ADHD. In order for this scale to hold the most value in the detection of 
malingering of ADHD and to prevent misuse of stimulants, it needs to meet certain criteria: The 
scale needs to be short, easy to administer, and score; it needs to be suitable for administration in 
the primary care setting, and should not need additional training for interpretation; it needs to be 
tailored toward patients reporting ADHD symptoms; and it should display good sensitivity to 
malingering. 
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METHODS 
2. Methods 
2.1 Study Design
This study employs a cross-sectional experimental design using a self-administered 
computer-based survey distributed to conveniently sampled groups of college-enrolled adults 
with and without ADHD. Approval was obtained from the University of Mississippi Institutional 
Review Board. 
2.2 Item Development 
Potential SAMS items were developed based on the Accuracy of Knowledge (AoK) 
framework, which says that malingerers can be identified by “the assessment of a person’s level 
of relevant knowledge of the target condition that the person is attempting to simulate.” (Lanyon, 
1997). New items were generated through an extensive literature review, and a series of in-depth 
interviews conducted with students with and without ADHD recruited from the University of 
Mississippi. Items from preexisting subtle scales such as the PAI, the MMPI, the Connor Adult 
ADHD Rating Scale (CAARS), and the Clinical Assessment of Attention Deficit – Adult (CAT-
A) which fit the AoK framework were also included in the initial item pool. Using a combination 
of new items and items borrowed from preexisting scales, a total of 125 items were generated in 
accordance with scale development guidelines developed by Jackson (1966), Buss (1959), 
Loevinger (1957), and Clark & Watson (1995). A 7-point response format from “Strongly 
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Disagree” to “Strongly Agree” was used in order to allow for for variability in responses 
(Comrey, 1988). Qualitative pretests were conducted using cognitive interviews to help refine 
the item pool. 
 
2.3 Experimental design 
This study employed a between-subjects design with alternate instruction sets (in both the 
quantitative pretest and the main data collection task). Similar techniques have been commonly 
used to develop and test subtle scales in extant literature (Cofer, Chance & Judson, 1949; 
Lanyon, 1970; Myerholtz & Rosenberg, 1997; Myerholtz & Rosenberg, 1998; Lees-Haley, 
English & Glenn, 1991; Wooley et al, 2012). Respondents were first asked to self-report 
diagnosis of ADHD. To validate self-reported ADHD, respondents were also asked time since 
ADHD diagnosis, time spent during ADHD diagnostic visit, and the specialty of the diagnosing 
practitioner. Respondents were then assigned to one of three groups as part of the experimental 
design.  
Respondents who self-reported ADHD were instructed to respond to the test item pool 
honestly; this was called the ADHD group. Respondents who self-reported not having ADHD 
were randomized to one of two groups where they were either instructed to fake ADHD on the 
test item pool (Malingerer group) (Quinn, 2003; Supplement 1), or instructed to respond honestly 
(Control group). Participants in the Malingerer group were not given information about 
symptoms of ADHD or other coaching to help them feign because research shows that 
knowledge of ADHD or coaching did not significantly improve success rate of ADHD feigning 
(Booksh et al., 2010; Rios & Morey, 2013; Tucha et al., 2009). Manipulation checks were 
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included to ensure that the instructions were followed. In addition to the item pool, the survey 
also measured the respondent’s demographics and several other variables such as insurance 
status, housing status, expected GPA, stimulant use behavior, and frequency of use of healthcare 
services. 
2.4 Pretest 
A quantitative pretest was conducted to narrow the item pool and to filter the questions 
that did not differentiate well between the study groups. A total of 278 students from the 
University of Mississippi were recruited using the SONA Systems website, a psychology 
department research platform. Participants were offered research credits as incentive for 
participation in the study. There were a total of 53 completed responses in the ADHD group, 111 
completed responses in the Malingerer group and 112 completed responses in the Control group. 
Using the Student’s t-test, 38 items were identified from the initial test pool that showed 
significant discrimination between the Malingerer group and the ADHD group. These items were 
entered into a Principal Components Analysis (PCA) to estimate the factor structure of the scale 
(Gerbing & Anderson, 1988; DeVellis, 2011). Only responses in the ADHD group and the 
Control group were used in the PCA, because literature suggests that malingering might cause 
distortions in the factor structure (Myerholtz & Rosenberg, 1997; Myerholtz & Rosenberg, 
1998). Items with loadings less than or equal to 0.4 or items loading heavily on more than one 
factor were deleted (Hinkin, 1995). Using a combination of the latent root criterion (or the 
eigenvalue greater than 1 rule) (Nunnally, 1978), the scree plot (Cattell, 1966) and parallel 
analysis (Franklin et al., 1995; O’Connor, 2000), two factors were obtained: a 6-item 
psychological factor, and a 4-item academic factor, named because of the content of the items 
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that loaded highly on each factor. Both factors demonstrated satisfactory reliability with a 
Cronbach’s alpha of 0.895 and 0.870, respectively. 
2.5 Participants and study recruitment 
For the main data collection task, a sample of the undergraduate population at the 
University of Mississippi was used. Subject recruitment was conducted through a series of 
announcements conducted in classes held across campus, in order to obtain a representative 
sample. All participants were offered extra course credit as an incentive for participation. In 
order to prevent coercion, students who did not wish to participate in the study were offered an 
opportunity to earn the same extra credit through comparable alternative assignments. Additional 
incentives, in the form of a chance to win one of five $25 gift cards, were offered to individuals 
assigned to the Malingerer group in order to match real world incentives for malingering. 
Interested students set up appointments with the research team, and completed the survey in 
person on a computer assigned to them. The survey was designed using Qualtrics, and all data 
were collected anonymously. 
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ANALYSIS 
3. Analysis
Analysis was conducted using IBM SPSS AMOS 22.0 (Chicago, Illinois) and MPlus 7.4 
(Muthen & Muthen). Descriptive statistics were calculated and compared across the three study 
groups. A confirmatory factor analysis (CFA) was conducted, in MPlus, using the factor 
structure obtained from the PCA in the pretest. Because the items were measured on an ordinal 
scale with limited response options, CFA was conducted using robust weighted least squares 
estimation (i.e., the WLSMV estimator in MPlus). This approach is recommended in cases of 
categorical outcome variables which violate the assumption of normal distribution (Newsom, 
2015; Rhemtulla, Brosseau-Liard, & Savalei, 2012). Similar to the pretest, only responses in the 
ADHD group and the Control group were used in the CFA, because literature suggests that 
Malingering might cause distortions in the factor structure (Myerholtz & Rosenberg, 1997; 
Myerholtz & Rosenberg, 1998).  
The loading estimates, standardized residuals and modification indices were used to 
identify items that can be considered for deletion. Model fit was estimated using the Chi Square 
statistic, the Comparative Fit Index (CFI), and the Root Mean Square Error of Approximation 
(RMSEA; Hair et al., 2006). Convergent validity and discriminant validity were estimated using 
the Gerbing & Anderson (1988) approach. The Fornell & Larcker (1981) approach to convergent 
and discriminant validity using Average Variance Extracted (AVE) was not applicable in this 
case because the CFA model was run using WLSMV estimators. Reliability for each factor was 
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assessed through Cronbach’s alpha and composite reliability (Hair et al, 2006; Fornell & 
Larcker, 1981)
.  
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RESULTS 
4. Results 
4.1 Sample Characteristics
A total of 637 respondents completed the survey. The respondent sample had a mean age 
of 20.5 years, was comprised of 63.6% females, 74.1% Caucasians, and 46.9% freshmen. 16.6% 
(106) of the sample self-reported ADHD, and 12.7% (81) self-reported other mental illnesses. 
Approximately 35% of sample self-reported misusing prescription stimulants. Eight respondents 
self-reported attempting to feign ADHD in a physician’s office. These 8 responses were 
excluded from all subsequent analyses because they do not belong in any one of the three 
predefined study groups. The breakdown of each of the demographic characteristics across the 
three study groups, and the significance of the difference between the three groups is provided in 
Table B1. 
Table B1: Demographics of the sample 
Characteristic 
ADHD       
N = 102 
Malingere
-rs 
N = 264 
Controls 
N = 259 
   
N (%) N (%) N (%) χ2 df p 
Age (Mean [SD]; F) 20.9[2.12
] 
20.5 [1.68] 20.5 
[1.73] 
2.38 2, 625 0.093 
Female 51 (49.5) 178 (68.2) 173 (65.5) 11.6
5 
2 0.003 
Ethnicity 
 
  28.2
0 
12 0.002 
         Caucasian 88 (85.4) 175 (67) 201 (75.8)    
         African American 6 (5.8) 51 (19.5) 36 (13.6)    
         Hispanic or Latino/a 2 (1.9) 5 (1.9) 0 (0)    
         Asian or Pacific Islander 2 (1.9) 22 (8.4) 19 (7.2)    
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         American Indian 0 (0) 1 (0.4) 0 (0)    
         Biracial or Multiracial 3 (2.9) 6 (2.3) 8 (3.0)    
         Other 2 (1.9) 0 (0.4) 1 (0.4)    
Greek membership 62 (60.2) 116 (44.6) 122 (46.0) 7.73 2 0.021 
School year 
 
  7.27 6 0.297 
          Freshman 42 (40.8) 119 (45.6) 135 (50.9)    
          Sophomore 28 (27.2) 57 (21.8) 62 (23.4)    
          Junior 20 (19.4) 60 (23.0) 41 (15.5)    
          Senior (and above) 13 (12.6) 25 (9.6) 27 (10.2)    
Residence 
 
  21.0
2 
10 0.021 
          On-campus residence hall 44 (42.7) 123 (47.1) 142 (53.6)    
          Fraternity/Sorority house 9 (8.7) 14 (5.4) 10 (3.8)    
          Other on-campus housing 1 (1.0) 12 (4.6) 1 (0.4)    
          Parent/Guardian home 1 (1.0) 7 (2.7) 3 (1.1)    
          Off-campus housing 48 (46.6) 103 (39.5) 107 (40.4)    
          Other 0 (0) 2 (0.8) 2 (0.8)    
Expected GPA    31.9
7 
6 <0.00
1          3.5 to 4 31 (30.1) 122 (46.9) 124 (47.0)    
         3 to 3.49 37 (35.9) 107 (41.2) 103 (39)    
         2.5 to 2.99 27 (26.2) 28 (10.8) 30 (11.4)    
         2 to 2.49 8 (7.8) 3 (1.2) 7 (2.7)    
         Below 2 0 (0) 0 (0) 0 (0)    
Insurance status    7.15 12 0.848 
         Private health insurance 
from parents/family 
80 (77.7)  181 (69.6) 194 (73.2)    
         Independent private health 
insurance plan 
7 (6.8) 14 (5.4) 15 (5.7)    
         Private health insurance 
from Employer 
4 (3.9) 15 (5.8) 14 (5.3)    
        No health insurance 5 (4.9) 14 (5.4) 13 (4.9)    
        State Medicaid plan 2 (1.9) 18 (6.9) 11 (4.2)    
        Medicare plan 1 (1.0) 8 (3.1) 7 (2.6)    
        Other 4 (3.9) 10 (3.8) 11 (4.2)    
Self-reported ADHD 103 (100) 0 (0) 0 (0) 629.
0 
2 <0.00
1 Other mental illnesses 31 (30.4) 23 (8.8) 27 (10.2) 33.2
7 
2 <0.00
1 Time since ADHD Diagnosis    - - - 
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        Less than 1 year ago 14 (13.9) - -    
        1 to 2 years ago 13 (12.9) - -    
        3 to 5 years ago 27 (26.7) - -    
        More than 5 years ago 47 (46.5) - -    
Type of physician who 
diagnosed ADHD 
   - - - 
        Primary Care Provider 11 (10.8) - -    
        Specialist 83 (81.4) - -    
        Not sure 8 (7.8) - -    
ADHD Diagnosis visit time    - - - 
       Less than 30 minutes 20 (19.4) - -    
       30 to 60 minutes 36 (35.0) - -    
       60 to 120 minutes 29 (28.2) - -    
       Greater than 120 minutes 10 (9.7) - -    
Emergency room visits in the 
past 6 months 
   12.6
8 
6 0.048 
        Never 67 (66.3) 150 (57.7) 171 (65.3)    
        1 to 3 times 29 (28.7) 106 (40.8) 86 (32.8)    
        4 to 6 times 4 (4.0) 4 (1.5) 5 (1.9)    
        More than 6 times 1 (1) 0 (0)  0 (0)    
Hospital Visits in the past 6 
months 
   1.99 2 0.369 
        Never 100 (98) 254 (98.1) 253 (96.2)    
        1 to 3 times 2 (2.0) 5 (1.9) 10 (3.8)    
        4 to 6 times 0 (0) 0 (0) 0 (0)    
        More than 6 times 0 (0) 0 (0) 0 (0)    
Office Visits in the past 6 
months 
 
  22.7
1 
6 <0.00
1         Never 10 (9.8) 49 (18.9) 55 (20.8)    
        1 to 3 times 63 (61.8) 182 (70.3) 173 (65.5)    
        4 to 6 times 23 (22.5) 24 (9.3) 31 (11.7)    
        More than 6 times 6 (5.9) 4 (1.5) 5 (1.9)    
Use of stimulants with a valid 
Rx 
96 (94.1) 9 (3.5) 4 (1.5) 503.
0 
4 <0.00
1 Use of stimulants without a 
valid Rx 
41 (40.2) 81 (31.2) 97 (36.6) 4.50 4 0.342 
Frequency of stimulants misuse    2.07 4 0.723 
            1 to 2 occasions 11 (27.5) 30 (37.0) 37 (38.9)    
            3 to 5 occasions 12 (30.0) 19 (23.5) 20 (21.1)    
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            6 or more occasions 17 (42.5) 32 (39.5) 38 (40.0)    
History of illegal use    28.1
6 
6 <0.00
1             Less than 1 year ago 8 (20.0) 40 (49.4) 40 (42.1)    
            1 to 2 years ago 15 (37.5) 27 (33.3) 42 (44.2)    
            3 to 5 years ago  8 (20.0) 11 (13.6) 11 (11.6)    
            More than 5 years ago 9 (22.5) 3 (3.7) 2 (2.1)    
Reasons for illegal use    - - - 
            Experimental 7 (17.5) 21 (25.9) 22 (23.2)    
            Academic 33 (82.5) 72 (88.9) 84 (88.4)    
            Entertainment 2 (0.05) 14 (17.3) 12 (12.6)    
            Other 7 (17.5) 4 (4.9) 7 (7.4)    
Source of stimulants    15.1
8 
6 0.019 
            Borrowed from 
family/friends 
27 (67.5) 67 (82.7) 76 (0.8)    
            Purchased from 
stranger/friend 
10 (25.0) 27 (33.3) 32 (33.7)    
           Pharmacy 9 (22.5) 1 (1.2) 1 (1.1)    
            Other 0 0 0    
ADHD: Attention Deficit Hyperactivity Disorder; SD: Standard Deviation; df: degrees of 
freedom; GPA: Grade Point Average 
 
4.2 Manipulation Checks 
The goal of the manipulation check was to ensure that the Malingerer group was 
following instructions to feign ADHD correctly. Items included in the manipulation check were 
those that were considered to be easy to feign; so the responses of the Malingerer group should 
resemble those of the ADHD group very closely. Table B2 shows the means, standard 
deviations, and p values of the differences between each of the three groups. Overall, it was 
found that the Malingerer group was not significantly different from the ADHD group on all but 
one of the items in the manipulation check, indicating that the instructions were clearly 
communicated and followed. 
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Table B2: Differences between the three groups among the items used in the Manipulation 
check 
Item ADHD  
Mean 
(SD) 
Malinge
-rer 
Mean 
(SD) 
Control 
Mean 
(SD) 
ADHD 
vs 
Maling
-erer p 
ADHD 
vs 
Control 
p 
Maling-
erer vs 
Control 
p 
I have ADD/ADHD 6.5 (0.9) 5.2 (1.5) 1.5 (1.1) <0.01 <0.01 <0.01 
I have difficulty keeping my 
focus while reading 
6.2 (0.9) 5.9 (1.1) 3.8 (1.8) 0.10 <0.01 <0.01 
I have trouble sitting still 5.8 (1.5) 5.6 (1.3) 3.3 (1.8) 0.61 <0.01 <0.01 
I tend to act impulsively 5.2 (1.8) 5.1 (1.3) 2.9 (1.7) 0.63 <0.01 <0.01 
I have trouble paying attention 
in class 
6.1 (0.9) 6.0 (1.0) 3.5 (1.8) 0.65 <0.01 <0.01 
Note: Each item was scored on a scale of 1 through 7. 
 
4.3 SAMS Items 
A total of 10 items were identified from the pretest using a combination of individual 
item discriminatory power and the principal components analysis (PCA). Model structure 
obtained from the PCA contained 2 factors, the psychological factor and the academic factor, 
with 6 items and 4 items, respectively. Confirmatory Factor Analysis (CFA) using the WLSMV 
estimator was conducted using the model structured obtained from the PCA. In this measurement 
model, each item was allowed to load on only one of the two factors; non-target loadings were 
fixed to zero. The chi square statistic for the model fit was found to be 108.153 (df = 34; p < 
0.0005), with a Root Mean Square Error of Approximation of 0.078 (90% CI=0.062-0.094), 
Weighted Root Mean Square Residual value of 0.752 and a comparative fit index of 0.986, 
indicating satisfactory model fit (Hair et al., 2006). Table B3 shows the mean sum subscale score 
for the psychological factor and the academic factor in each of the study groups. Both factors 
significantly differentiated all three study groups in post-hoc comparisons. The Malingerer group 
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scored significantly higher than the two other groups on both factors, indicating the ability of the 
SAMS to identify malingering behavior. 
 
Table B3: Mean sum scale scores on each factor of the Subtle ADHD Malingering 
Screener (SAMS) in each study group 
Group Psychological factor 
Mean (SD) 
Academic factor 
Mean (SD) 
ADHD group 19.7 (7.0) 10.6 (5.6) 
Malingerer group 26.4 (7.1) 15.8 (5.7) 
Control group 11.0 (5.8) 5.5 (3.0) 
Total 18.9 (9.6) 10.7 (6.7) 
Note: Both the psychological factor and the academic factor significantly differentiated all 
three study groups in post-hoc comparisons (p < 0.05). 
Note: The minimum and maximum possible score for each subscale are: Psychological factor 
= 6 – 42; Academic factor = 4 – 28. 
 
4.4 Psychometric properties 
Cronbach’s alpha for the psychological subscale was found to be 0.909, and that for the 
academic subscale was found to be 0.916, indicating satisfactory reliability scores. Convergent 
validity was demonstrated by the consistently high factor loadings for each item in the scale, as 
seen in Table B4. The correlation between the two subscales was found to be 0.793. The 
MODEL TEST option in MPlus was used to test if the correlation between the two latent 
variables was different from 1. With a p-value less than 0.0005, the correlation was shown to be 
significantly different from 1 indicating significant discriminant validity.  
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Table B4: Means, standard deviations, and effect sizes for each of the three study groups on 
each item in the Subtle ADHD Malingering Scale (SAMS) 
Item Subscale 
Standar-
dized 
loadings 
ADHD 
Mean 
(SD) 
Malinger
-er Mean 
(SD) 
Control 
Mean 
(SD) 
ADHD vs 
Malingere
-r d 
ADHD vs 
Control   
d 
Malingere
-r vs 
Control d 
Item 1 PSYCH 0.772 3.9 (1.9) 5.2 (1.4) 2.1 (1.6) -0.81 1.11 4.53 
Item 2 PSYCH 0.652 4.2 (1.9) 5.1 (1.6) 2.6 (1.9) -0.51 0.83 4.39 
Item 3 PSYCH 0.842 3.0 (1.7) 4.4 (1.7) 1.6 (1.1) -0.84 1.14 3.37 
Item 4 PSYCH 0.721 2.2 (1.6) 3.4 (1.7) 1.5 (1.2) -0.67 0.53 2.57 
Item 5 PSYCH 0.759 2.8 (1.6) 4.1 (1.6) 1.6 (1.1) -0.83 0.90 3.28 
Item 6 PSYCH 0.875 3.5 (1.6) 4.3 (1.6) 1.7 (1.3) -0.44 1.33 3.59 
Item 7 ACAD 0.763 2.8 (2.1) 4.2 (1.7) 1.5 (1.0) -0.73 0.97 3.18 
Item 8 ACAD 0.899 2.5 (1.6) 3.8 (1.7) 1.3 (0.8) -0.75 1.08 2.83 
Item 9 ACAD 0.883 2.8 (1.8) 4.1 (1.7) 1.3 (0.9) -0.79 1.15 3.10 
Item 10 ACAD 0.925 2.5 (1.6) 3.8 (1.7) 1.4 (0.9) -0.76 0.95 2.88 
Note: All items significantly differentiated all three groups in post-hoc analyses; Factor scores are 
the standardized factor estimates obtained from the Confirmatory Factor Analysis. ‘d’ indicates 
effect size. 
Note: Items have been blinded to protect the distribution of the scale. Please contact the authors 
for the full scale. 
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DISCUSSION 
5. Discussion
 This study is the first of its kind to develop a scale tailored toward identification of 
malingering in ADHD. As such, it offers great potential for direct use in the clinical setting. A 
ten-item, two-factor solution was obtained for the SAMS in this study. The CFA showed 
satisfactory model fit. With an RMSEA of 0.078 and a CFI value of 0.986, the SAMS scale 
meets the Hair et al. (2006) criteria of an RMSEA value less than 0.1 and a CFI greater than 0.9 
necessary for a satisfactory model fit (Hair et al., 2006). Each of the ten items in the final factor 
solution showed high factor loadings (>0.6), and significant differentiation among the three study 
groups. The scale showed satisfactory reliability (Cronbach’s alpha > 0.9), and construct validity 
(AVE > 0.5) validity (Hair et al., 2006). Each individual SAMS item was also found to 
significantly differentiate all three groups in the study, and not just the ADHD group and the 
Malingerer group.  
The sum scale score was used to calculate the total score for the SAMS in order to 
preserve ease of scoring, and reduce time of administration in the physician’s office. The mean 
scores on both the psychological and academic factor follow patterns predicted by Lanyon 
(1997) in the Accuracy of Knowledge framework. The Malingerer group consistently endorsed 
items more than the ADHD group or the Control group, and this response behavior can help 
identify the Malingerer group. 
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The respondent sample obtained in this study is fairly representative of the demographics 
of the University of Mississippi’s student population (University of Mississippi Office of 
Institutional Research, Effectiveness, and Planning, 2016). Several of the demographic 
characteristics were found to be significantly different among the three study groups. While 
some of these, such as a higher incidence of comorbid mental illnesses in the ADHD group 
versus other groups, were expected, some others, such as higher Greek membership in the 
ADHD group, were unexpected. More than 35 of the sample self-report misuse of stimulants 
which was in line with findings from Garnier-Dykstra et al. (2012). Over 80% of the individuals 
in the ADHD group were diagnosed by a specialist, and more than 80% also spent greater than 
30 minutes during their ADHD diagnosis visit. About 46% of the ADHD group were also 
diagnosed over 5 years ago. These findings support the validity of the self-reported ADHD 
measure against the presence of possible malingerers within the ADHD group.  
 The success of the experimental design was crucial to the development of the SAMS. The 
five items used in the manipulation check clearly indicate that the instructions used in the 
Malingerer group were simple, clear, and easy to follow. However, the Malingerer group and the 
ADHD group significantly differed (p < 0.01; Table 3) on one manipulation check item: “I have 
ADD/ADHD.” This finding was not unexpected, because the instructions provided to the 
malingerers asked them to imagine visiting the physician in order to obtain an ADHD diagnosis, 
implying that they had not been diagnosed yet (See supplement-1 for the Malingerer instruction 
set).   
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5.1 Limitations 
 This scale was developed using an experimental design, rather than a real-world 
malingerer population. This design was chosen to facilitate ease of identification of the 
malingerers and to help provide the required sample size in the Malingerer group. Despite the 
use of additional incentives, the Malingerer group in the study may not have been representative 
of the true malingerer population in the real world. The experimental design also prioritizes 
internal validity over external validity, which makes it difficult to generalize the psychometrics 
of the SAMS, calculated from one University population, to the real world setting. Finally, the 
ability of the SAMS to detect malingering of ADHD reduces potential access points for abusers, 
but does not directly reduce the problem of prescription stimulant abuse. Further testing and 
interventions need to be developed in order to achieve that goal. 
5.2 Clinical Implications and Future Research 
 The SAMS presents an innovative approach to identify malingering of ADHD symptoms, 
reduce overdiagnosis of ADHD, and for early identification of prescription stimulant abuse 
directly in the clinical setting.  It is designed to be short, inexpensive, and does not need 
additional training for administration, scoring or evaluation. These features make it a valuable 
resource for primary care providers. While further research is needed to develop a cutoff score, 
and calculate the sensitivity and specificity of the SAMS, this study shows the potential this scale 
holds for future clinical use. Future research in this area needs to test the ability of SAMS to 
resist faking in the real world and compare it with existing subtle scales that may be used for 
similar purposes. There is also a need to focus on the needs of malingerers identified by this 
scale, and to develop interventions that can help malingerers cope with their stressors and 
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address potential addiction problems. Finally, this study successfully demonstrates the 
methodology of developing a subtle scale with the application of a theoretical framework for 
item development. This technique can be applied in several other areas in healthcare such as the 
early identification of opioid abusers, injection drug users, and others to implement early 
targeted interventions
.  
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APPENDIX – A: Malingerer Group Instructions 
 
“Imagine yourself having trouble in school. Things aren’t working out as you planned but your 
counselor’s only advice is to buckle down. You want to get some help. You hear about adult 
ADHD on a television show. When talking to a friend about it, your friend tells you that you 
could get special accommodations from the university, like untimed tests and rescheduling of 
exams if two are given on the same day. Your friend adds that the stimulant medications that are 
generally prescribed have minimal side effects and that you can take the medicine only when you 
need it, just for school. You decide to read a book on ADHD. You find out that some ADHD 
adults even collect social security benefits. You conclude that you have enough of the symptoms. 
You convince yourself that you have ADHD. You go to the doctor and you really want to get 
help. In order to get these benefits, you need to convincingly act like a person who has ADHD.” 
   
Source: Quinn, C. A. (2003). Detection of malingering in assessment of adult ADHD. Archives 
of Clinical Neuropsychology, 18(4), 379-395. 
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ABSTRACT 
Objective Development of a cut-off score and psychometric testing of the Subtle ADHD 
Malingering Screener (SAMS), and comparison of its diagnostic accuracy with the Personality 
Inventory Assessment – Adult (PAI). 
Method This study employs a cross-sectional experimental design using a self-administered 
computer-based survey distributed to conveniently sampled groups of college students with and 
without ADHD. Respondents were classified into three experimental groups: an ADHD group, a 
Control group, and a Malingerer group, comprised of individuals who were instructed to feign 
ADHD. ROC curve analysis and CART analysis were used to determine a cutoff score. 
Diagnostic accuracy of the SAMS was compared to the Personality Assessment Inventory – 
Adult.  
Results Using a combination of ROC curve analysis and CART analysis, respondents were 
classified as malingerers if their SAMS psychological factor score was greater than 15, and the 
SAMS academic factor score was greater than 7. The sensitivity of the SAMS for detecting 
malingering was found to be 90.4%, with a specificity of 80.1%. The SAMS showed superior 
performance compared to the PAI, as it had significantly higher sensitivity (90% vs 51%; p < 
0.0005). 
Conclusion This is the first study to estimate the diagnostic accuracy of the SAMS. The SAMS 
is recommended for use in the primary care setting setting to identify patients who need 
additional testing to confirm an ADHD diagnosis. Further research is needed to test the 
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generalizability of these findings. The SAMS can help reduce overdiagnosis of ADHD and 
potential misuse of stimulants by helping to identify malingering of ADHD symptoms.
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INTRODUCTION 
1. Introduction
Exaggeration of symptoms of Attention Deficit Hyperactivity Disorder (ADHD) or 
malingering of ADHD in the physician’s office is prevalent in 20 to 50% of college students 
(Suhr et al., 2008; Sullivan, May & Galbally, 2007; Harrison, 2006) and is on the rise due to the 
increasing abuse of prescription stimulants and the presence of external incentives to encourage 
malingering (Chen et al., 2016; Slick, Sherman & Iverson, 1999; Binder, 1992). Most attempts to 
malinger ADHD are successful because research suggests that faking of ADHD symptoms is 
fairly easy (Quinn, 2003; Fisher & Watkins, 2008; Harp et al., 2011; Jachimowicz & Geiselman, 
2004).  
1.1 Challenges in Detection of ADHD Malingering 
Tools commonly used for confirming a diagnosis of ADHD include several scales such as 
self-report inventories, observer symptom ratings, cognitive measures, test of executive 
functions, and symptom validity tests (SVTs). Several researchers have shown that most of these 
tools have poor sensitivity toward malingering. Self-report inventories such as the ADHD 
Behavior Checklist have been shown to be ineffective at detection of malingering (Quinn, 2003).  
Jachimowicz & Geiselman (2004) found that the falsification rate, or the percentage of students 
who can successfully malinger on a given instrument, was 65% on the Wender Utah Rating 
Scale (WURS), 75% on the ADHD Rating Scale IV (ARS), 90% on the Conners Adult ADHD 
Rating Scale (CAARS), and 95% on the Brown Adult ADHD Scale (BAAS). Fisher & Watkins 
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(2008) found that 77% and 93% of students successfully faked on the ADHD behavior checklist 
and the College ADHD Response Evaluation (CARE).  
SVTs are the only tools that have been shown to offer moderately good sensitivities toward 
malingering (Sollman, Ranseen & Berry, 2010). Quinn (2003) found that the Integrated Visual 
and Auditory Continuous Performance Test (IVA CPT) had sensitivity and specificity above 
90%. Rios & Morey (2013) found that the subtle scales such as Negative Impression scale (NIM) 
and Rogers Discriminant Function (RDF) subscales of the Personal Assessment Inventory (PAI) 
showed satisfactory sensitivity (64% and 84%, respectively). Marshall et al. (2010) found that 
combining two or more SVTs, or one SVT and one cognitive test, can offer sensitivities and 
specificities in the range of 95% and 98% respectively. Harrison, Edwards & Parker (2007) 
found that malingerers obtained higher scores on the CAARS and lower scores on the Woodcock 
Johnson Psychoeducational Battery – III (WJPB – III), than individuals who have ADHD, and 
proposed that these two tests be used in combination to identify malingerers. However, Jasinski 
et al. (2011) tested a wide range of behavioral rating scales, cognitive tests, and SVTs and found 
that most students were able to fake their symptoms on the all the scales tested. Though there is a 
lack of consensus in the literature, some SVTs, and some cognitive tests, may offer adequate 
sensitivity to malingering. However, their potential is limited by their drawbacks. SVTs and 
other cognitive performance tests are time consuming, complex, impose heavy respondent 
burden and often need computerized testing and scoring and require training for interpretation of 
scores. 
1.2 Subtle Scales 
Subtlety in scale development is the lack of face validity in the items of a given instrument. It 
is defined as “degree to which the psychopathological meaning of an item can be determined in 
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an a priori fashion” (Burkhart, Gynther & Christian, 1978). The disadvantages of SVTS can be 
overcome by subtle scales. Subtle scales hold an advantage over traditional SVTs in detecting 
malingering because their lack of face validity makes faking un-intuitive. Most subtle scales 
suffer from poor sensitivity at detecting malingering of ADHD because they were not 
specifically developed to detect malingering in the context of ADHD (Musso & Gouvier, 2012). 
The newly developed subtle scale, the Subtle ADHD Malingering Scale (SAMS), grounded in 
the Accuracy of Knowledge framework (Lanyon, 1997), was developed for to be a short, simple, 
and easy tool for administration in the clinical setting to detect malingering of ADHD. This scale 
was also shown to have acceptable factor validity, reliability, and construct validity 
(Ramachandran et al., in preparation).  
1.3 Objective 
This study aims to calculate the sensitivity and specificity of the SAMS to malingering of 
ADHD and to test its resistance to malingering compared to the PAI.
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METHODS 
2. Methods 
2.1 Study Design
This study employed a cross-sectional, experimental design using a self-administered, 
computer-based survey distributed to conveniently sampled groups of college-enrolled adults 
with and without ADHD. The study design and sample were previously explained in detail in 
Ramachandran et al. (in preparation). Approval was obtained from the University of Mississippi 
IRB.  
2.2 Study Participants and Data Collection 
 This study sampled from the undergraduate population at the University of Mississippi. 
Students with ADHD and students without ADHD were both sampled in order to identify the 
scale’s ability to differentiate individuals who actually have ADHD from those who are 
malingering symptoms. Respondents were assigned to one of three groups as part of the 
experimental design. Respondents who self-reported ADHD were instructed to respond to the 
test item pool honestly; this was called the ADHD group. Respondents who self-reported not 
having ADHD were randomized to one of two groups where they were either instructed to fake 
ADHD on the test item pool, called the Malingerer group, or instructed to respond honestly, 
called the Control group. Self-reported ADHD was validated by asking respondents the time 
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since their ADHD diagnosis, the time spent during ADHD diagnostic visit, and the specialty of 
the diagnosing practitioner. 
Study recruitment was conducted through a series of announcements conducted in classes 
held across the campus of University of Mississippi, in order to obtain a representative sample. 
All participants were offered extra course credit as an incentive for participation. Additional 
incentives, in the form of a chance to win one out of five $25 gift cards, were offered to 
individuals assigned to the Malingerer group in order to match real world incentives for 
malingering. Interested students set up appointments with the research team, and completed the 
survey in person on a computer assigned to them. The survey was designed using Qualtrics, and 
all data were collected anonymously.  
2.3 Survey Design 
Respondents were asked to indicate their age, gender, ADHD diagnosis, and other 
demographic information before responding to the SAMS. To provide a comparator to the 
SAMS, the Personality Assessment Inventory – Adult (PAI - A) was administered at the end of 
the survey. The PAI was chosen because it contains multiple validity scales such as the Negative 
Impression scale (NIM), the Positive Impression Scale (PIM), the Malingering Index (MAL) and 
the Rogers Discriminant Function (RDF). These subscales showed satisfactory sensitivity and 
specificity toward malingering of ADHD (Rios & Morey, 2013).  
2.4 Data Analysis 
All data were analyzed using IBM SPSS (Chicago, IL). Demographic characteristics 
were compared across all three study groups using t-test and chi square, as appropriate.  
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2.4.1 Selecting a Cut-off Point 
 In order to calculate an optimal cut-off point, a combination of ROC curve analysis and 
CART analysis was used. ROC curve analysis is the most popular technique for estimating an 
efficient cut-off score for a diagnostic test (Fletcher, Fletcher & Fletcher, 2014). However, the 
items in the SAMS are expected to have different distributions because they were grounded in 
different constructs of the Accuracy of Knowledge framework (Lanyon, 1997; Ramachandran et 
al., in preparation). Using a total scale score of such a combination of items to calculate a cut-off 
point might cause a loss in the detail of information provided by each type of question. In order 
to effectively utilize all the subscales of the SAMS to provide a simple, but effective scoring 
algorithm, Classification and Regression Trees (CART) analysis was also used in the calculation 
of a cut-off score (Moisen, 2008).  
CART analysis is an advanced technique of calculating cut-off points for scales that 
attempt to distinguish one group of individuals from another (Breiman et al., 1984). It provides 
results which can be simple, yet powerful and easily visualized, especially in cases where more 
than two groups might be present in the data (Franck, 2013). Weigel, Meston & Rosen (2005) 
recommend that a combination of ROC analysis followed by CART analysis be used to estimate 
cut-off points. Following the estimation of a cut-off score, psychometric indices such as 
sensitivity, specificity, false positive rate, and false negative rate were calculated. The ability of 
the scale to resist malingering can be estimated from the falsification rate or the false negative 
rate. 
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2.4.2 Comparison with Pre-existing Scales 
The comparison of the performance of the SAMS and the PAI was conducted using a 
concordance & discordance analysis, as used in Myerholtz & Rosenberg (1997). To compare the 
degree of correspondence between the two screening instruments, a phi coefficient (Cheetam & 
Hazel, 1969; Kuhn, 1973) and a Cohen’s kappa (Cohen, 1960) were calculated. The McNemar 
test was also used to compare the sensitivity & specificity of the two scales (Cheetam & Hazel, 
1969).
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RESULTS 
3. Results 
3.1 Demographic characteristics
The data collection effort resulted in a total of 637 completed responses. The 
demographic characteristics of the respondents are presented in Table 1. The respondent sample 
had a mean age of 20.5 years, was comprised of 63.6% females, 74.1% Caucasians, and 46.9% 
freshmen. 16.6% (106) of the sample self-reported ADHD, and 12.7% (81) self-reported other 
mental illnesses. 35.3% of the total sample self-reported misusing prescription stimulants. Eight 
respondents self-reported attempting to feign ADHD in a physician’s office. These 8 responses 
were excluded from all subsequent analyses because they did not fit into any one of the three 
predefined study groups. The breakdown of each of the demographic characteristics across the 
three study groups is provided in Table C1. 
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Table C1: Demographics of the sample 
Characteristic 
ADHD       
N = 102 
Malingere
rs 
N = 264 
Controls 
N = 259 
   
N (%) N (%) N (%) χ2 df p 
Age (Mean [SD]; F) 20.9[2.12
] 
20.5 [1.68] 20.5 
[1.73] 
2.38 2, 625 0.093 
Female 51 (49.5) 178 (68.2) 173 (65.5) 11.6
5 
2 0.003 
Ethnicity 
 
  28.2
0 
12 0.002 
         Caucasian 88 (85.4) 175 (67) 201 (75.8)    
         African American 6 (5.8) 51 (19.5) 36 (13.6)    
         Hispanic or Latino/a 2 (1.9) 5 (1.9) 0 (0)    
         Asian or Pacific Islander 2 (1.9) 22 (8.4) 19 (7.2)    
         American Indian 0 (0) 1 (0.4) 0 (0)    
         Biracial or Multiracial 3 (2.9) 6 (2.3) 8 (3.0)    
         Other 2 (1.9) 0 (0.4) 1 (0.4)    
Greek membership 62 (60.2) 116 (44.6) 122 (46.0) 7.73 2 0.021 
School year 
 
  7.27 6 0.297 
          Freshman 42 (40.8) 119 (45.6) 135 (50.9)    
          Sophomore 28 (27.2) 57 (21.8) 62 (23.4)    
          Junior 20 (19.4) 60 (23.0) 41 (15.5)    
          Senior (and above) 13 (12.6) 25 (9.6) 27 (10.2)    
Residence 
 
  21.0
2 
10 0.021 
          On-campus residence hall 44 (42.7) 123 (47.1) 142 (53.6)    
          Fraternity/Sorority house 9 (8.7) 14 (5.4) 10 (3.8)    
          Other on-campus housing 1 (1.0) 12 (4.6) 1 (0.4)    
          Parent/Guardian home 1 (1.0) 7 (2.7) 3 (1.1)    
          Off-campus housing 48 (46.6) 103 (39.5) 107 (40.4)    
          Other 0 (0) 2 (0.8) 2 (0.8)    
Expected GPA    31.9
7 
6 <0.00
1          3.5 to 4 31 (30.1) 122 (46.9) 124 (47.0)    
         3 to 3.49 37 (35.9) 107 (41.2) 103 (39)    
         2.5 to 2.99 27 (26.2) 28 (10.8) 30 (11.4)    
         2 to 2.49 8 (7.8) 3 (1.2) 7 (2.7)    
         Below 2 0 (0) 0 (0) 0 (0)    
Insurance status    7.15 12 0.848 
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         Private health insurance 
from parents/family 
80 (77.7)  181 (69.6) 194 (73.2)    
         Independent private health 
insurance plan 
7 (6.8) 14 (5.4) 15 (5.7)    
         Private health insurance 
from Employer 
4 (3.9) 15 (5.8) 14 (5.3)    
        No health insurance 5 (4.9) 14 (5.4) 13 (4.9)    
        State Medicaid plan 2 (1.9) 18 (6.9) 11 (4.2)    
        Medicare plan 1 (1.0) 8 (3.1) 7 (2.6)    
        Other 4 (3.9) 10 (3.8) 11 (4.2)    
Self-reported ADHD 103 (100) 0 (0) 0 (0) 629.
0 
2 <0.00
1 ADHD: Attention Deficit Hyperactivity Disorder; SD: Standard Deviation; df: degrees of 
freedom; GPA: Grade Point Average 
 
3.2 Estimation of a Cut-off Score & Psychometric Indices 
 As seen in Figure 1, the ROC Curve analysis using the total sum scale score of the 
SAMS was found to provide significant discrimination between the malingerers and the honest 
respondents, with an area under the curve of 0.901 (Standard error: 0.012; p: < 0.0001). The 
selected cut-off from the ROC curve analysis was a total SAMS score greater than 27; 
respondents greater than this score were classified as malingerers. This score offered a sensitivity 
of 89.2% and a specificity of 77.8%.  
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NOTE: AUC = 0.901; Standard error = 0.0.012; p < 0.0001 
 
The risk estimate for the CART analysis, as seen in figure 2, was 0.239, with a standard 
error of 0.017. The cutoff score obtained from CART analysis utilized each individual factor 
score. Respondents were classified as malingerers if their psychological scale score was greater 
than 15 and the academic scale score was greater than 7. This classification provided a sensitivity 
of 90.3% and a specificity of 80.1%, both superior to the results of the ROC curve analysis. For 
the remainder of this study, the classification algorithm from the CART analysis was used for the 
SAMS scores. Given these values of sensitivity & specificity, the classification algorithm 
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provided by the CART analysis was found to have a false positive rate of 19.9% and a false 
negative rate of 9.7%.  
Figure 2: CART Analysis Tree diagram 
 
NOTE “Psych”: Psychological subscale; “Acad”: Academic subscale 
 
The results of the CART analysis can also be used to differentiate all three study groups. 
The respondents who score less than or equal to 15 on the Psychological factor are comprised of 
a majority of the Control group, and those scoring greater than 15 on the Psychological factor 
and less than or equal to 7 on the Academic factor were mostly comprised of the ADHD group. 
The classification accuracy of the ROC curve analysis and the CART analysis in each study 
subgroup is provided in Table C2. 
 
ADHD group: 102
Malingerer group: 264
Control group: 258
Study Subgroup (N)
ADHD group: 28
Malingerer group: 15
Control group: 212
Psych ≤ 15
ADHD group: 74
Malingerer group: 249
Control group: 46
Psych > 15
ADHD group: 25
Malingerer group: 10
Control group: 23
Acad ≤ 7
ADHD group: 49
Malingerer group: 239
Control group: 23
Acad > 7
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Table C2: Classification accuracy of the SAMS and PAI in each study group 
Scale/Group ADHD group 
N (%) 
Malingerer group  
N (%) 
Control group  
N (%) 
ROC curve classification 
     Malingerer 56 (56.6) 231 (89.2) 22 (8.7) 
     Honest respondent 43 (43.4) 28 (10.8) 231 (91.3) 
Total 99 259 253 
CART classification 
     Malingerer 48 (48.5) 234 (90.3) 22 (8.7)  
     Honest respondent 51 (51.5) 25 (9.7) 231 (91.3) 
Total 99 259 253 
PAI classification 
     Malingerer 14 (15.1) 129 (50.6) 23 (9.2) 
     Honest respondent 79 (84.9) 126 (49.4) 226 (90.8) 
Total 93 255 249 
NOTE: ROC curve classification rule: Total SAMS score greater than 27; CART 
classification rule: SAMS psychological factor score greater than 15 and SAMS academic 
factor score greater than 7; PAI classification rule: Negative Impression Scale score greater 
than 92 or Malingering scale score greater than 3. The “total” provi 
ded is the number of completed respondents for each scale, which is different for the PAI and 
the SAMS. 
 
3.3 Comparator Scale 
 This study used the PAI as a comparator to the SAMS. The classification rules for the 
PAI were obtained from previous research identifying malingering of ADHD using the PAI 
(Rios & Morley, 2013). Rios & Morley (2013) used three rules to classify a PAI respondent as a 
malingerer: a Negative Impression Scale (NIM) score greater than 92, and a Malingering (MAL) 
scale score greater than 3, and a Roger’s Discriminant Function (RDF) greater than 0. However, 
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because the RDF was based on a large number of items, each with possible missing values, there 
were a large number of missing values in the RDF variable; and it had to be dropped from the 
classification rule. In order to provide the PAI the best chance of identifying malingerers, a rule 
of either an NIM score greater than 92 or a MAL score greater than 3 was used, essentially 
stacking the odds against the SAMS. Using this classification rule, the PAI provided a sensitivity 
of 51.0% and a specificity of 89.2%. 
The total degree of agreement between the PAI and the SAMS was found to be (417 out 
of 592) 70.4%. A phi coefficient of 0.455 and a Cohen’s kappa of 0.408 were found for the two 
scales, indicating a moderate degree of agreement. The McNemar test was also used to compare 
the sensitivity and the specificity of the two scales. The SAMS was shown to have significantly 
higher sensitivity (p < 0.0005) and lower specificity (p < 0.0005) than the PAI. 
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DISCUSSION 
4. Discussion
 This study provides critical research for the further development of the Subtle ADHD 
Malingering Scale (SAMS) and builds value for its use in the clinical setting. The study used 
data collected in the Ramachandran et al. (in preparation) research study to develop a cut-off 
score for SAMS and estimate its classification accuracy. A combination of ROC curve analysis 
and CART analysis were used to estimate the cut-off score. The CART analysis classification 
rule showed moderate improvement over that of the ROC curve analysis in terms of sensitivity 
and specificity. But the CART analysis is truly superior to the ROC curve analysis because it 
utilizes separate scoring rules for each of the factors in the SAMS, thereby making it harder to 
fake. It also provides an opportunity to distinguish all three study groups, instead of merely the 
malingerer group. This ability can provide advantages in the clinical setting to distinguish the 
two honest study groups: the ADHD group and the Control group. Attempts to classify all three 
groups might also provide further confirmation of the ADHD diagnosis in the physician’s office. 
The multiple cut off scores provided by the CART analysis can also make it harder to ‘coach’ to 
malinger on the SAMS, because successful malingering will require that the scores fall within a 
narrower range.  
The CART classification rule comes with its own drawbacks. The risk estimate from the 
CART analysis was found to be 0.239, indicating that 23.9% of the respondent pool was 
misclassified by this technique. The misclassification rate is highest in the ADHD group at 
 
 
109 
 
48.5%. This high false positive rate among ADHD respondents indicates that the results of the 
SAMS should be interpreted with caution in the clinical setting. Being classified as a 
‘malingerer’ by the SAMS at a physician’s office should signal the need for additional testing, or 
a referral to a specialist, in the case of primary care providers.  This recommendation for 
additional testing can maximize efficiency of resource use by only recommending additional 
testing or referral in some of the patients reporting ADHD symptoms, instead of all of them.  
The comparator scale used in this study, the PAI, contains 348 items and includes a 
complex scoring algorithm. As such its utility in the physician’s office is limited. Rios & Morley 
(2013) found that the NIM scale provided a sensitivity and specificity of 64% and 73%, 
respectively, while the MAL scale provided a sensitivity and specificity of 38% and 81%. This 
study used a combination of the NIM and the MAL scales to identify malingering and found a 
sensitivity and specificity of 51% and 89%, respectively. Despite using fewer items, the SAMS 
showed superiority over the PAI at identifying malingering of ADHD, demonstrating the value 
of a scale that is tailored toward malingering of ADHD symptoms. The PAI had a significantly 
higher specificity than the SAMS, but this is caused by the fact that the PAI classifies so few 
respondents as malingerers (as seen in the high false negative rate), that most of the non-
malingerer population was correctly classified. 
4.1 Limitations 
 While demonstrating the potential of the SAMS to address malingering of ADHD, this 
study carries certain limitations. The data collection for this study was conducted along with the 
development of the SAMS itself (Ramachandran et al., in preparation). Further research needs to 
be conducted in diverse populations to test the applicability and generalizability of these results. 
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The comparability of the malingerer group used in this study to the real world malingerer 
population is unknown. Psychometric indices such as positive predictive value could not be 
calculated from this study because of the lack of an accurate estimate of the prevalence of 
malingering.  
4.2 Clinical Implications & Future Research 
 The SAMS presents immense potential for use in the clinical setting to help identify 
malingering of ADHD. It is tailored toward malingering of ADHD symptoms, and has 
demonstrated satisfactory sensitivity, specificity, and high resistance to malingering. Physicians 
evaluating patients for ADHD are recommended to administer the SAMS, pending further 
research, to help validate the veracity of the patient’s claims. Patients flagged as ‘malingerers’ by 
the SAMS are recommended for additional testing or referral to a specialist to identify if they 
truly have ADHD. There is a need for further research testing the SAMS directly in the clinical 
setting and in diverse populations. There is also a need to develop interventions for patients 
identified as ‘malingerers’ by the SAMS. These individuals may need help for drug dependence 
and counseling to help them cope with the stressors that have encouraged drug-seeking behavior.
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CHAPTER 5 
SUMMARY, CONCLUSIONS, AND FUTURE RESEARCH 
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CONCLUSIONS 
This dissertation explores a growing problem in society with regard to prescription drugs. 
The study was unique in that it chose to focus on prescription stimulants, rather than the opioids 
which has been the focus of most recent research in this field of study. This dissertation is the 
first study of its kind to attempt to address the issue of prescription stimulant abuse by 
developing techniques to identify individuals attempting to inappropriately access stimulants. 
Two different techniques were explored in this study: the first used administrative claims data to 
classify individual stimulant users using a latent class analysis; and the second attempted to 
develop a short subtle scale called the Subtle ADHD Malingering Screener (SAMS) for 
administration in the primary care provider’s office to identify individuals malingering 
symptoms of ADHD with the intentions of obtaining prescriptions of stimulants for misuse or 
diversion. 
The specific goal of this dissertation was to help develop strategies that can be used in the 
prevention of abuse of prescription psychostimulants. The combination of techniques 
developed/tested in this dissertation provide a health policy analyst with tools, such as the 
SAMS, and the prescription claims based latent classes, required to develop these strategies. 
These tools still need several rounds of further research before they can be used in strategies 
tailored for drug abuse prevention, but this dissertation will hopefully serve as the platform for 
the development and refinement of these tools. The conclusions from each of the three papers are 
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discussed below, along with directions for future research and the clinical implications of this 
dissertation. 
Concluding Comments on Paper One 
This paper developed a deeper understanding of the differences in stimulant use 
behaviors between abusers and non-abusers, using a latent class analysis to first classify 
individuals according to their behaviors. It is one of the first studies to attempt to exclusively 
characterize stimulant use behaviors, and validate the developed latent classes using stimulant 
abuse diagnoses identified from administrative claims data. The use of administrative claims data 
to identify misusers of prescription stimulants revealed critical insights that can help future 
research in this area. This study was also the first to use a combination of Medicaid 
administrative claims data and PMP data to comprehensively capture all use of stimulants while 
estimating the risk behaviors.  
This study developed a 2-class model with 4.1% of the sample in the one class, and 
95.9% of the sample in the other class. The 2-class model, however, was not predictive of a 
diagnosis of dependent or nondependent stimulant abuse. It is possible that many individuals 
classified in Class 1 were in fact abusing prescription stimulants, but had not been diagnosed; 
Unfortunately, there was no way to know their true misuse status from the data. Hence the 
findings of the prediction of stimulant misuse using latent classes need to be treated with caution. 
It is possible that alternative validation mechanisms with more reliable identification of misusers 
might have discovered a correlation with the latent classes obtained in this study. It is possible 
that any combination of these reasons was responsible for the non-significant finding obtained in 
this study. The latent classes obtained in this study might still be indicative of stimulant misuse, 
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but further research into the stimulant use behavior, perhaps using alternative validation 
techniques, is needed. This study demonstrated the value of latent class techniques to help 
identify variations in patterns of stimulant use, while also displaying the limitations of 
administrative claims databases in capturing true misuse status.  
 
Concluding comments on Paper Two 
This study is the first of its kind to attempt to develop a scale to identify malingering in 
the context of ADHD. A ten-item, two-factor solution was obtained for the SAMS in this study. 
The sum scale score was used to calculate the total score for the SAMS in order to preserve ease 
of scoring, and reduce time of administration in the physician’s office. Each individual SAMS 
item was also found to significantly differentiate all three groups in the study, and not just the 
ADHD group and the Malingerer group. The mean scores on both the psychological and 
academic factor follow patterns predicted in the Accuracy of Knowledge framework. 
The SAMS presents an innovative approach to identify malingering of ADHD symptoms, 
reduce overdiagnosis of ADHD, and for early identification of prescription stimulant abuse 
directly in the clinical setting.  It is designed to be short, inexpensive, and does not need 
additional training for administration, scoring, or evaluation, which makes it a valuable resource 
for primary care providers. There is a need to focus on the needs of malingerers identified by this 
scale, and to develop interventions that can help malingerers cope with their stressors and 
address potential addiction problems. Finally, this study successfully demonstrates the 
methodology of developing a subtle scale with the application of a theoretical framework for 
item development. This technique can be applied in other areas in such as the early identification 
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of opioid abusers, injection drug users, to implement early targeted interventions. Further 
research required on the SAMS was conducted as part of paper three, as presented below. 
 
Concluding comments on Paper Three 
This study provides critical research for the further development of the Subtle ADHD 
Malingering Scale (SAMS) and builds value for its use in the clinical setting. The study used 
data collected in paper two to develop a cut-off score for SAMS and estimate its classification 
accuracy. Using CART analysis, a cut off score was developed for the SAMS. Respondents were 
classified as malingerers if their psychological subscale score was greater than 15 and the 
academic subscale score was greater than 7. This classification provided a sensitivity of 90.3% 
and a specificity of 80.1%. The SAMS also showed significantly higher sensitivity than the PAI. 
Being classified as a ‘malingerer’ by the SAMS at a physician’s office should signal the need for 
additional testing, or a referral to a specialist, in the case of primary care providers.
The SAMS presents immense potential for use in the clinical setting to help identify 
malingering of ADHD. It is tailored toward malingering of ADHD symptoms, and has 
demonstrated satisfactory sensitivity, specificity, and high resistance to malingering. Physicians 
evaluating patients for ADHD are recommended to administer the SAMS, pending further 
research, to help validate the veracity of the patient’s claims. Patients flagged as ‘malingerers’ by 
the SAMS are recommended for additional testing or referral to a specialist to identify if they 
truly have ADHD. There is a need for further research testing the SAMS directly in the clinical 
setting and in diverse populations. There is also a need to develop interventions for patients 
identified as ‘malingerers’ by the SAMS. These individuals may need help for drug dependence 
and counseling to help them cope with the stressors that have encouraged drug-seeking behavior.  
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IMPLICATIONS 
Implications for Research & Practice 
This dissertation was carried out with the goal of making a change in the healthcare 
system that contributes to millions of cases of prescription stimulant abuse every year. The latent 
classes developed in paper one, with further refinement, can provide a tool to payers such as 
commercial insurance companies or Medicaid to help identify individuals who are in need of 
intervention for drug abuse, and to help curtail others who may be diverting their prescriptions. 
Once the identification of these individuals can be accomplished with reasonable accuracy, 
tailored interventions need to be developed that involve a combination of lock-in programs to 
prevent further drug diversion, and medical intervention to help treat possible drug abuse 
problems. Further research is needed to develop validation tools that can estimate if latent classes 
using behavioral risk factors can perform reliably at identifying individuals who are misusing or 
diverting stimulant prescriptions.  
Papers two and three serve a different purpose in the prevention of drug abuse. They used 
a college student population, to help develop a tool for use in the physician’s office to help 
identify malingerers of ADHD symptoms. This can help address overdiagnosis of ADHD, and 
over-prescribing of stimulants. The SAMS displayed potential for clinical use with high levels of 
sensitivity and specificity.. A true estimate of prevalence of malingering in various settings needs 
to be estimated to calculate a positive and negative predictive value that can help direct 
recommendations for the individuals identified by SAMS. Further testing in other populations 
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including children under the age of 18 years, and adults not enrolled in colleges is required 
before the SAMS can be recommended in the clinical setting.  
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